{
"instance": {
"esmc-20220630.htm": {
"axisCustom": 1,
"axisStandard": 16,
"contextCount": 101,
"dts": {
"calculationLink": {
"local": [
"esmc-20220630_cal.xml"
]
},
"definitionLink": {
"local": [
"esmc-20220630_def.xml"
]
},
"inline": {
"local": [
"esmc-20220630.htm"
]
},
"labelLink": {
"local": [
"esmc-20220630_lab.xml"
]
},
"presentationLink": {
"local": [
"esmc-20220630_pre.xml"
]
},
"schema": {
"local": [
"esmc-20220630.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
"https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
"https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
"https://xbrl.sec.gov/country/2022/country-2022.xsd",
"https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
]
}
},
"elementCount": 508,
"entityCount": 1,
"hidden": {
"http://fasb.org/us-gaap/2022": 21,
"http://www.escalonmed.com/20220630": 3,
"http://xbrl.sec.gov/dei/2022": 13,
"total": 37
},
"keyCustom": 16,
"keyStandard": 269,
"memberCustom": 9,
"memberStandard": 27,
"nsprefix": "esmc",
"nsuri": "http://www.escalonmed.com/20220630",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:EntityRegistrantName",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "0001001 - Document - Cover",
"role": "http://www.escalonmed.com/role/Cover",
"shortName": "Cover",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:EntityRegistrantName",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R10": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:NatureOfOperations",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2101101 - Disclosure - Organization and Description of Business",
"role": "http://www.escalonmed.com/role/OrganizationandDescriptionofBusiness",
"shortName": "Organization and Description of Business",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:NatureOfOperations",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R11": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2103102 - Disclosure - Going concern (Notes)",
"role": "http://www.escalonmed.com/role/GoingconcernNotes",
"shortName": "Going concern (Notes)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R12": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2105103 - Disclosure - Significant Accounting Policies",
"role": "http://www.escalonmed.com/role/SignificantAccountingPolicies",
"shortName": "Significant Accounting Policies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R13": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2122104 - Disclosure - Intangible assets (Notes)",
"role": "http://www.escalonmed.com/role/IntangibleassetsNotes",
"shortName": "Intangible assets (Notes)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R14": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2125105 - Disclosure - Accrued expense (Notes)",
"role": "http://www.escalonmed.com/role/AccruedexpenseNotes",
"shortName": "Accrued expense (Notes)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R15": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2128106 - Disclosure - Line of credit (Notes)",
"role": "http://www.escalonmed.com/role/LineofcreditNotes",
"shortName": "Line of credit (Notes)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R16": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LongTermDebtTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2130107 - Disclosure - Long-term Debt (Notes)",
"role": "http://www.escalonmed.com/role/LongtermDebtNotes",
"shortName": "Long-term Debt (Notes)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LongTermDebtTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R17": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2134108 - Disclosure - Capital Stock Transactions",
"role": "http://www.escalonmed.com/role/CapitalStockTransactions",
"shortName": "Capital Stock Transactions",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R18": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2139109 - Disclosure - Income Taxes",
"role": "http://www.escalonmed.com/role/IncomeTaxes",
"shortName": "Income Taxes",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R19": {
"firstAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2145110 - Disclosure - Commitments and Contingencies",
"role": "http://www.escalonmed.com/role/CommitmentsandContingencies",
"shortName": "Commitments and Contingencies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R2": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "i333651defbd74bb3a10570e15e1a61f4_I20220927",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "dei:EntityCommonStockSharesOutstanding",
"reportCount": 1,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "false",
"longName": "0002002 - Document - Document And Entity Information",
"role": "http://www.escalonmed.com/role/DocumentAndEntityInformation",
"shortName": "Document And Entity Information",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"lang": "en-US",
"name": "dei:EntityCurrentReportingStatus",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R20": {
"firstAnchor": null,
"groupType": "disclosure",
"isDefault": "false",
"longName": "2146111 - Disclosure - Retirement and post retirement plans (Notes)",
"role": "http://www.escalonmed.com/role/RetirementandpostretirementplansNotes",
"shortName": "Retirement and post retirement plans (Notes)",
"subGroupType": "",
"uniqueAnchor": null
},
"R21": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2150112 - Disclosure - Related Party Transactions",
"role": "http://www.escalonmed.com/role/RelatedPartyTransactions",
"shortName": "Related Party Transactions",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R22": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2152113 - Disclosure - Concentration of credit risk (Notes)",
"role": "http://www.escalonmed.com/role/ConcentrationofcreditriskNotes",
"shortName": "Concentration of credit risk (Notes)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R23": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LesseeOperatingLeasesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2155114 - Disclosure - Leases (Notes)",
"role": "http://www.escalonmed.com/role/LeasesNotes",
"shortName": "Leases (Notes)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LesseeOperatingLeasesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R24": {
"firstAnchor": {
"ancestors": [
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2206201 - Disclosure - Significant Accounting Policies (Policies)",
"role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies",
"shortName": "Significant Accounting Policies (Policies)",
"subGroupType": "policies",
"uniqueAnchor": {
"ancestors": [
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R25": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2307301 - Disclosure - Significant Accounting Policies (Tables)",
"role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesTables",
"shortName": "Significant Accounting Policies (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R26": {
"firstAnchor": {
"ancestors": [
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2308302 - Disclosure - Significant Accounting Policies Property Plant and Equipment (Tables)",
"role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentTables",
"shortName": "Significant Accounting Policies Property Plant and Equipment (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R27": {
"firstAnchor": {
"ancestors": [
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
"reportCount": 1,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2309303 - Disclosure - Significant Accounting Policies Deferred revenue (Tables)",
"role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesDeferredrevenueTables",
"shortName": "Significant Accounting Policies Deferred revenue (Tables)",
"subGroupType": "tables",
"uniqueAnchor": null
},
"R28": {
"firstAnchor": {
"ancestors": [
"div",
"us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "i0997c3821afd4fa4acbfcd00c4a56489_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2323304 - Disclosure - Intangible assets (Tables)",
"role": "http://www.escalonmed.com/role/IntangibleassetsTables",
"shortName": "Intangible assets (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"div",
"us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "i0997c3821afd4fa4acbfcd00c4a56489_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R29": {
"firstAnchor": {
"ancestors": [
"div",
"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"reportCount": 1,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2326305 - Disclosure - Accrued expense (Tables)",
"role": "http://www.escalonmed.com/role/AccruedexpenseTables",
"shortName": "Accrued expense (Tables)",
"subGroupType": "tables",
"uniqueAnchor": null
},
"R3": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:AuditorName",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "false",
"longName": "0003009 - Document - Audit Information",
"role": "http://www.escalonmed.com/role/AuditInformation",
"shortName": "Audit Information",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:AuditorName",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R30": {
"firstAnchor": {
"ancestors": [
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2332307 - Disclosure - Long-term Debt EIDL maturities (Tables)",
"role": "http://www.escalonmed.com/role/LongtermDebtEIDLmaturitiesTables",
"shortName": "Long-term Debt EIDL maturities (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R31": {
"firstAnchor": {
"ancestors": [
"us-gaap:IncomeTaxDisclosureTextBlock",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2340309 - Disclosure - Income Taxes (Tables)",
"role": "http://www.escalonmed.com/role/IncomeTaxesTables",
"shortName": "Income Taxes (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:IncomeTaxDisclosureTextBlock",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R32": {
"firstAnchor": null,
"groupType": "disclosure",
"isDefault": "false",
"longName": "2347310 - Disclosure - Retirement and post retirement plans (Tables)",
"role": "http://www.escalonmed.com/role/RetirementandpostretirementplansTables",
"shortName": "Retirement and post retirement plans (Tables)",
"subGroupType": "tables",
"uniqueAnchor": null
},
"R33": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2353311 - Disclosure - Concentration of credit risk (Tables)",
"role": "http://www.escalonmed.com/role/ConcentrationofcreditriskTables",
"shortName": "Concentration of credit risk (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R34": {
"firstAnchor": {
"ancestors": [
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LeaseCostTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2357312 - Disclosure - Leases (Tables)",
"role": "http://www.escalonmed.com/role/LeasesTables",
"shortName": "Leases (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LeaseCostTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R35": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "i5ce9c5d17502418e900723a665b14bca_D20200701-20210630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "esmc:PPPloanamount",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2402401 - Disclosure - Organization and Description of Business (Details)",
"role": "http://www.escalonmed.com/role/OrganizationandDescriptionofBusinessDetails",
"shortName": "Organization and Description of Business (Details)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R36": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:RetainedEarningsAccumulatedDeficit",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2404402 - Disclosure - Going concern (Details)",
"role": "http://www.escalonmed.com/role/GoingconcernDetails",
"shortName": "Going concern (Details)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R37": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:RestrictedCash",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2410403 - Disclosure - Significant Accounting Policies (Cash and Cash Equivalents) (Details)",
"role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails",
"shortName": "Significant Accounting Policies (Cash and Cash Equivalents) (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "i55ba5c960ec34d6ca2592f9f812b66e8_I20200630",
"decimals": "0",
"lang": "en-US",
"name": "us-gaap:RestrictedCash",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R38": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:InventoryNet",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2411404 - Disclosure - Significant Accounting Policies (Inventory) (Details)",
"role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesInventoryDetails",
"shortName": "Significant Accounting Policies (Inventory) (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"lang": "en-US",
"name": "us-gaap:InventoryValuationReserves",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R39": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:TradeAndOtherAccountsReceivablePolicy",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2412405 - Disclosure - Significant Accounting Policies (Accounts Receivable) (Details)",
"role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails",
"shortName": "Significant Accounting Policies (Accounts Receivable) (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:TradeAndOtherAccountsReceivablePolicy",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R4": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1001003 - Statement - Consolidated Balance Sheets",
"role": "http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"shortName": "Consolidated Balance Sheets",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"lang": "en-US",
"name": "us-gaap:RestrictedCashCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R40": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"ix:continuation",
"us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2414407 - Disclosure - Significant Accounting Policies (Net Income (loss) Per Share) (Details)",
"role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails",
"shortName": "Significant Accounting Policies (Net Income (loss) Per Share) (Details)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R41": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"ix:continuation",
"us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2415408 - Disclosure - Significant Accounting Policies Earning per share details (Details)",
"role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails",
"shortName": "Significant Accounting Policies Earning per share details (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"ix:continuation",
"us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": "0",
"lang": "en-US",
"name": "us-gaap:PreferredStockDividendsIncomeStatementImpact",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R42": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:PropertyPlantAndEquipmentTextBlock",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:PropertyPlantAndEquipmentGross",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2418411 - Disclosure - Significant Accounting Policies Property pant and equipment (Details)",
"role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails",
"shortName": "Significant Accounting Policies Property pant and equipment (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:PropertyPlantAndEquipmentTextBlock",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:PropertyPlantAndEquipmentGross",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R43": {
"firstAnchor": {
"ancestors": [
"us-gaap:AdvertisingCostsPolicyCapitalizedDirectResponseAdvertising",
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "i5ce9c5d17502418e900723a665b14bca_D20200701-20210630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:AdvertisingExpense",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2419412 - Disclosure - Significant Accounting Policies advertising expense (Details)",
"role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesadvertisingexpenseDetails",
"shortName": "Significant Accounting Policies advertising expense (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"us-gaap:AdvertisingCostsPolicyCapitalizedDirectResponseAdvertising",
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "i5ce9c5d17502418e900723a665b14bca_D20200701-20210630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:AdvertisingExpense",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R44": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:DeferredRevenue",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2420413 - Disclosure - Significant Accounting Policies deferred revenue (Details)",
"role": "http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails",
"shortName": "Significant Accounting Policies deferred revenue (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
"div",
"ix:continuation",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:DeferredRevenue",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R45": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:FiniteLivedIntangibleAssetsNet",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2424415 - Disclosure - Intangible assets (Details)",
"role": "http://www.escalonmed.com/role/IntangibleassetsDetails",
"shortName": "Intangible assets (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
"div",
"us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "-6",
"lang": "en-US",
"name": "esmc:Finitelivedtangibleassetsaccumulatedimpairment",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R46": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"div",
"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2427416 - Disclosure - Accrued expense (Details)",
"role": "http://www.escalonmed.com/role/AccruedexpenseDetails",
"shortName": "Accrued expense (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"div",
"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R47": {
"firstAnchor": {
"ancestors": [
"span",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2429417 - Disclosure - Line of credit (Details)",
"role": "http://www.escalonmed.com/role/LineofcreditDetails",
"shortName": "Line of credit (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R48": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherLongTermDebt",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2433418 - Disclosure - Long-term Debt (Details)",
"role": "http://www.escalonmed.com/role/LongtermDebtDetails",
"shortName": "Long-term Debt (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"span",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "-3",
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherLongTermDebt",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R49": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "2",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"reportCount": 1,
"unitRef": "usdPerShare",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2436419 - Disclosure - Capital Stock Transactions (Stock Option Plans) (Narrative) (Details)",
"role": "http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails",
"shortName": "Capital Stock Transactions (Stock Option Plans) (Narrative) (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"lang": "en-US",
"name": "esmc:ShareBasedCompensationArrangementbyShareBasedPaymentAwardUnvested",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R5": {
"firstAnchor": null,
"groupType": "statement",
"isDefault": "false",
"longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
"role": "http://www.escalonmed.com/role/ConsolidatedBalanceSheetsParenthetical",
"shortName": "Consolidated Balance Sheets (Parenthetical)",
"subGroupType": "parenthetical",
"uniqueAnchor": null
},
"R50": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"reportCount": 1,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2437420 - Disclosure - Capital Stock Transactions (Stock Option Activity) (Details)",
"role": "http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails",
"shortName": "Capital Stock Transactions (Stock Option Activity) (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:StockholdersEquityNoteDisclosureTextBlock",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": "0",
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R51": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
"us-gaap:IncomeTaxDisclosureTextBlock",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2441422 - Disclosure - Income Taxes (Provision for Income Taxes) (Details)",
"role": "http://www.escalonmed.com/role/IncomeTaxesProvisionforIncomeTaxesDetails",
"shortName": "Income Taxes (Provision for Income Taxes) (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
"us-gaap:IncomeTaxDisclosureTextBlock",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R52": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"us-gaap:IncomeTaxDisclosureTextBlock",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
"reportCount": 1,
"unique": true,
"unitRef": "number",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2442423 - Disclosure - Income Taxes (Effective Income Tax Rate) (Details)",
"role": "http://www.escalonmed.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails",
"shortName": "Income Taxes (Effective Income Tax Rate) (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"us-gaap:IncomeTaxDisclosureTextBlock",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
"reportCount": 1,
"unique": true,
"unitRef": "number",
"xsiNil": "false"
}
},
"R53": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2443424 - Disclosure - Income Taxes (Components of Net Deferred Income Tax Assets and Liabilities) (Details)",
"role": "http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails",
"shortName": "Income Taxes (Components of Net Deferred Income Tax Assets and Liabilities) (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R54": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:DeferredTaxAssetsValuationAllowance",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2444425 - Disclosure - Income Taxes Operation loss carry forward (Details)",
"role": "http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails",
"shortName": "Income Taxes Operation loss carry forward (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "i27ca5ac4331c4d47a6e68ff5c094cb43_I20220630",
"decimals": "0",
"lang": "en-US",
"name": "us-gaap:OperatingLossCarryforwards",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R55": {
"firstAnchor": null,
"groupType": "disclosure",
"isDefault": "false",
"longName": "2448426 - Disclosure - Retirement and post retirement plans (Details)",
"role": "http://www.escalonmed.com/role/RetirementandpostretirementplansDetails",
"shortName": "Retirement and post retirement plans (Details)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R56": {
"firstAnchor": null,
"groupType": "disclosure",
"isDefault": "false",
"longName": "2449427 - Disclosure - Retirement and post retirement plans - liability rollforward (Details)",
"role": "http://www.escalonmed.com/role/RetirementandpostretirementplansliabilityrollforwardDetails",
"shortName": "Retirement and post retirement plans - liability rollforward (Details)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R57": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:RelatedPartyTransactionDueFromToRelatedParty",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2451428 - Disclosure - Related Party Transactions (Details)",
"role": "http://www.escalonmed.com/role/RelatedPartyTransactionsDetails",
"shortName": "Related Party Transactions (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:RelatedPartyTransactionDueFromToRelatedParty",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R58": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "i5ce9c5d17502418e900723a665b14bca_D20200701-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ConcentrationRiskSupplier",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2454429 - Disclosure - Concentration of credit risk (Details)",
"role": "http://www.escalonmed.com/role/ConcentrationofcreditriskDetails",
"shortName": "Concentration of credit risk (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "i5ce9c5d17502418e900723a665b14bca_D20200701-20210630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ConcentrationRiskSupplier",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R59": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShortTermLeasePayments",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2458430 - Disclosure - Leases (Details)",
"role": "http://www.escalonmed.com/role/LeasesDetails",
"shortName": "Leases (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShortTermLeasePayments",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R6": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1003005 - Statement - Consolidated Statements Of Operations",
"role": "http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations",
"shortName": "Consolidated Statements Of Operations",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R7": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "icc77d57b592b4da38f1922dc1ece93c3_I20200630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:PreferredStockSharesOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1004006 - Statement - Consolidated Statements Of Shareholders' Equity and Comprehensive Loss",
"role": "http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss",
"shortName": "Consolidated Statements Of Shareholders' Equity and Comprehensive Loss",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "icc77d57b592b4da38f1922dc1ece93c3_I20200630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:PreferredStockSharesOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R8": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"ix:continuation",
"us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1005007 - Statement - Consolidated Statements Of Cash Flows",
"role": "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows",
"shortName": "Consolidated Statements Of Cash Flows",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": "0",
"lang": "en-US",
"name": "us-gaap:ProvisionForDoubtfulAccounts",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R9": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ia00f9a3f1387409caee5c94d8c4f5992_I20220630",
"decimals": "0",
"first": true,
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1006008 - Statement - Consolidated Statements Of Cash Flows (Parenthetical)",
"role": "http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
"shortName": "Consolidated Statements Of Cash Flows (Parenthetical)",
"subGroupType": "parenthetical",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "esmc-20220630.htm",
"contextRef": "ie1a117f2351d41c5b8c60b55d7ec7084_D20210701-20220630",
"decimals": "0",
"lang": "en-US",
"name": "us-gaap:InterestPaidNet",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
}
},
"segmentCount": 36,
"tag": {
"country_US": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "UNITED STATES",
"terseLabel": "Domestic [Member]"
}
}
},
"localname": "US",
"nsuri": "http://xbrl.sec.gov/country/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "domainItemType"
},
"dei_AmendmentFlag": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag",
"terseLabel": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_AuditorFirmId": {
"auth_ref": [
"r582",
"r583",
"r584"
],
"lang": {
"en-us": {
"role": {
"documentation": "PCAOB issued Audit Firm Identifier",
"label": "Auditor Firm ID",
"terseLabel": "Auditor Firm ID"
}
}
},
"localname": "AuditorFirmId",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/AuditInformation"
],
"xbrltype": "nonemptySequenceNumberItemType"
},
"dei_AuditorLocation": {
"auth_ref": [
"r582",
"r583",
"r584"
],
"lang": {
"en-us": {
"role": {
"label": "Auditor Location",
"terseLabel": "Auditor Location"
}
}
},
"localname": "AuditorLocation",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/AuditInformation"
],
"xbrltype": "internationalNameItemType"
},
"dei_AuditorName": {
"auth_ref": [
"r582",
"r583",
"r584"
],
"lang": {
"en-us": {
"role": {
"label": "Auditor Name",
"terseLabel": "Auditor Name"
}
}
},
"localname": "AuditorName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/AuditInformation"
],
"xbrltype": "internationalNameItemType"
},
"dei_CityAreaCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code",
"terseLabel": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/Cover",
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CoverAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Cover page.",
"label": "Cover [Abstract]"
}
}
},
"localname": "CoverAbstract",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"xbrltype": "stringItemType"
},
"dei_CurrentFiscalYearEndDate": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "End date of current fiscal year in the format --MM-DD.",
"label": "Current Fiscal Year End Date",
"terseLabel": "Current Fiscal Year End Date"
}
}
},
"localname": "CurrentFiscalYearEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "gMonthDayItemType"
},
"dei_DocumentAnnualReport": {
"auth_ref": [
"r582",
"r583",
"r584"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as an annual report.",
"label": "Document Annual Report",
"terseLabel": "Document Annual Report"
}
}
},
"localname": "DocumentAnnualReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentFiscalPeriodFocus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
"label": "Document Fiscal Period Focus",
"terseLabel": "Document Fiscal Period Focus"
}
}
},
"localname": "DocumentFiscalPeriodFocus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "fiscalPeriodItemType"
},
"dei_DocumentFiscalYearFocus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
"label": "Document Fiscal Year Focus",
"terseLabel": "Document Fiscal Year Focus"
}
}
},
"localname": "DocumentFiscalYearFocus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "gYearItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.",
"label": "Document Period End Date",
"terseLabel": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "dateItemType"
},
"dei_DocumentTransitionReport": {
"auth_ref": [
"r585"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as a transition report.",
"label": "Document Transition Report",
"terseLabel": "Document Transition Report"
}
}
},
"localname": "DocumentTransitionReport",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentType": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type",
"terseLabel": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/Cover",
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address, Address Line One",
"terseLabel": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/Cover",
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address, City or Town",
"terseLabel": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/Cover",
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address, Postal Zip Code",
"terseLabel": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/Cover",
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address, State or Province",
"terseLabel": "Entity Address, State or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/Cover",
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r581"
],
"lang": {
"en-us": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key",
"terseLabel": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityCommonStockSharesOutstanding": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
"label": "Entity Common Stock, Shares Outstanding",
"terseLabel": "Entity Common Stock, Shares Outstanding"
}
}
},
"localname": "EntityCommonStockSharesOutstanding",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/Cover",
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "sharesItemType"
},
"dei_EntityCurrentReportingStatus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Current Reporting Status",
"terseLabel": "Entity Current Reporting Status"
}
}
},
"localname": "EntityCurrentReportingStatus",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r581"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company",
"terseLabel": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/Cover"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number",
"terseLabel": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityFilerCategory": {
"auth_ref": [
"r581"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Filer Category",
"terseLabel": "Entity Filer Category"
}
}
},
"localname": "EntityFilerCategory",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/Cover"
],
"xbrltype": "filerCategoryItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation, State or Country Code",
"terseLabel": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/Cover",
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityInteractiveDataCurrent": {
"auth_ref": [
"r586"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
"label": "Entity Interactive Data Current",
"terseLabel": "Entity Interactive Data Current"
}
}
},
"localname": "EntityInteractiveDataCurrent",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/Cover",
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityPublicFloat": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
"label": "Entity Public Float",
"terseLabel": "Entity Public Float"
}
}
},
"localname": "EntityPublicFloat",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/Cover",
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "monetaryItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r581"
],
"lang": {
"en-us": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name",
"terseLabel": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/Cover"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityShellCompany": {
"auth_ref": [
"r581"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
"label": "Entity Shell Company",
"terseLabel": "Entity Shell Company"
}
}
},
"localname": "EntityShellCompany",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntitySmallBusiness": {
"auth_ref": [
"r581"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
"label": "Entity Small Business",
"terseLabel": "Entity Small Business"
}
}
},
"localname": "EntitySmallBusiness",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r581"
],
"lang": {
"en-us": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number",
"terseLabel": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/Cover",
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "employerIdItemType"
},
"dei_EntityVoluntaryFilers": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
"label": "Entity Voluntary Filers",
"terseLabel": "Entity Voluntary Filers"
}
}
},
"localname": "EntityVoluntaryFilers",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/Cover",
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityWellKnownSeasonedIssuer": {
"auth_ref": [
"r587"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
"label": "Entity Well-known Seasoned Issuer",
"terseLabel": "Entity Well-known Seasoned Issuer"
}
}
},
"localname": "EntityWellKnownSeasonedIssuer",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/Cover"
],
"xbrltype": "yesNoItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number",
"terseLabel": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2022",
"presentation": [
"http://www.escalonmed.com/role/Cover",
"http://www.escalonmed.com/role/DocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"esmc_AccountsPayableBenchmarkMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Accounts Payable Benchmark [Member]",
"label": "Accounts Payable Benchmark [Member]",
"terseLabel": "Accounts Payable Benchmark [Member]"
}
}
},
"localname": "AccountsPayableBenchmarkMember",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "domainItemType"
},
"esmc_AdvertisingcostsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Advertising costs [Abstract]",
"label": "Advertising costs [Abstract]",
"terseLabel": "Advertising costs [Abstract]"
}
}
},
"localname": "AdvertisingcostsAbstract",
"nsuri": "http://www.escalonmed.com/20220630",
"xbrltype": "stringItemType"
},
"esmc_AuditInformationAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Audit Information",
"label": "Audit Information [Abstract]"
}
}
},
"localname": "AuditInformationAbstract",
"nsuri": "http://www.escalonmed.com/20220630",
"xbrltype": "stringItemType"
},
"esmc_ConcentrationofcreditrisksAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Concentration of credit risks [Abstract]",
"label": "Concentration of credit risks [Abstract]",
"terseLabel": "Concentration of credit risks [Abstract]"
}
}
},
"localname": "ConcentrationofcreditrisksAbstract",
"nsuri": "http://www.escalonmed.com/20220630",
"xbrltype": "stringItemType"
},
"esmc_ConvertiblePreferredStockPercentageOfOutstandingSharesOfCommonStockUponConversion": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion",
"label": "Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion",
"terseLabel": "Convertible Preferred Stock, Percentage Of Outstanding Shares Of Common Stock Upon Conversion"
}
}
},
"localname": "ConvertiblePreferredStockPercentageOfOutstandingSharesOfCommonStockUponConversion",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "percentItemType"
},
"esmc_CustomerOneMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Customer One [Member]",
"label": "Customer One [Member]",
"terseLabel": "Customer One [Member]"
}
}
},
"localname": "CustomerOneMember",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "domainItemType"
},
"esmc_DisposeLeaseLiabilities": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "DisposeLeaseLiabilities",
"label": "DisposeLeaseLiabilities",
"terseLabel": "Dispose lease liability"
}
}
},
"localname": "DisposeLeaseLiabilities",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
],
"xbrltype": "monetaryItemType"
},
"esmc_DisposeROUassets": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "DisposeROUassets",
"label": "DisposeROUassets",
"terseLabel": "Dispose right-of-use assets"
}
}
},
"localname": "DisposeROUassets",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
],
"xbrltype": "monetaryItemType"
},
"esmc_DocumentAndEntityInformationAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Document and entity information [Abstract].",
"label": "Document And Entity Information [Abstract]",
"terseLabel": "Document And Entity Information [Abstract]"
}
}
},
"localname": "DocumentAndEntityInformationAbstract",
"nsuri": "http://www.escalonmed.com/20220630",
"xbrltype": "stringItemType"
},
"esmc_EIDLMaturitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "EIDL Maturities [Abstract]",
"label": "EIDL Maturities [Abstract]",
"terseLabel": "EIDL Maturities [Abstract]"
}
}
},
"localname": "EIDLMaturitiesAbstract",
"nsuri": "http://www.escalonmed.com/20220630",
"xbrltype": "stringItemType"
},
"esmc_EIDLMonthlyPaymentincludingPrincipalandInterest": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "MonthlyFixedPayment",
"label": "EIDL Monthly Payment including Principal and Interest",
"terseLabel": "EIDL Monthly Payment including Principal and Interest"
}
}
},
"localname": "EIDLMonthlyPaymentincludingPrincipalandInterest",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtDetails"
],
"xbrltype": "monetaryItemType"
},
"esmc_EarningpershareAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Earning per share [Abstract]",
"label": "Earning per share [Abstract]",
"terseLabel": "Earning per share [Abstract]"
}
}
},
"localname": "EarningpershareAbstract",
"nsuri": "http://www.escalonmed.com/20220630",
"xbrltype": "stringItemType"
},
"esmc_ExercisePriceRangeOneMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Exercise Price, Range One [Member]",
"label": "Exercise Price, Range One [Member]",
"terseLabel": "Exercise Price, Range One [Member]"
}
}
},
"localname": "ExercisePriceRangeOneMember",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails",
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"esmc_ExercisePriceRangeThreeMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "$4.97 to $5.59 [Member]",
"label": "Exercise Price, Range Three [Member]",
"terseLabel": "Exercise Price, Range Three [Member]"
}
}
},
"localname": "ExercisePriceRangeThreeMember",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails",
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"esmc_ExpirationPeriodOneMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Expiration Period, One [Member]",
"label": "Expiration Period, One [Member]",
"terseLabel": "Expiration Period, One [Member]"
}
}
},
"localname": "ExpirationPeriodOneMember",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails"
],
"xbrltype": "domainItemType"
},
"esmc_ExpirationPeriodTwoMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Expiration Period, Two [Member]",
"label": "Expiration Period, Two [Member]",
"terseLabel": "Expiration Period, Two [Member]"
}
}
},
"localname": "ExpirationPeriodTwoMember",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails"
],
"xbrltype": "domainItemType"
},
"esmc_Finitelivedintangibleassetsnetofimpairment": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Finite-lived intangible assets, net of impairment",
"label": "Finite-lived intangible assets, net of impairment",
"terseLabel": "Finite-lived intangible assets, net of impairment"
}
}
},
"localname": "Finitelivedintangibleassetsnetofimpairment",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsDetails"
],
"xbrltype": "monetaryItemType"
},
"esmc_Finitelivedtangibleassetsaccumulatedimpairment": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Finite-lived tangible assets, accumulated impairment",
"label": "Finite-lived tangible assets, accumulated impairment",
"terseLabel": "Finite-lived tangible assets, accumulated impairment"
}
}
},
"localname": "Finitelivedtangibleassetsaccumulatedimpairment",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsDetails"
],
"xbrltype": "monetaryItemType"
},
"esmc_GoingconcernAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Going concern [Abstract]",
"label": "Going concern [Abstract]",
"terseLabel": "Going concern [Abstract]"
}
}
},
"localname": "GoingconcernAbstract",
"nsuri": "http://www.escalonmed.com/20220630",
"xbrltype": "stringItemType"
},
"esmc_Interestportioninthefutureleasepayments": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Interest portion in the future lease payments",
"label": "Interest portion in the future lease payments",
"terseLabel": "Interest portion in the future lease payments"
}
}
},
"localname": "Interestportioninthefutureleasepayments",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/LeasesDetails"
],
"xbrltype": "monetaryItemType"
},
"esmc_Leases842Abstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Leases 842 [Abstract]",
"label": "Leases 842 [Abstract]",
"terseLabel": "Leases 842 [Abstract]"
}
}
},
"localname": "Leases842Abstract",
"nsuri": "http://www.escalonmed.com/20220630",
"xbrltype": "stringItemType"
},
"esmc_MaximumMaturityOfHighlyLiquidInvestmentsPeriod": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Maximum maturity of highly liquid investments, period.",
"label": "Maximum Maturity of Highly Liquid Investments, Period",
"terseLabel": "Maximum maturity of highly liquid investments, period"
}
}
},
"localname": "MaximumMaturityOfHighlyLiquidInvestmentsPeriod",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails"
],
"xbrltype": "durationItemType"
},
"esmc_NetOperatingLossExpirationPeriod": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Net Operating Loss, Expiration Period",
"label": "Net Operating Loss, Expiration Period",
"terseLabel": "Net Operating Loss, Expiration Period"
}
}
},
"localname": "NetOperatingLossExpirationPeriod",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails",
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails"
],
"xbrltype": "durationItemType"
},
"esmc_Netpresentvalueofnewleasefuturepayments": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Net present value of new lease future payments",
"label": "Net present value of new lease future payments",
"terseLabel": "Net present value of new lease future payments"
}
}
},
"localname": "Netpresentvalueofnewleasefuturepayments",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/LeasesDetails"
],
"xbrltype": "monetaryItemType"
},
"esmc_Newleaseliabilities": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "New lease liabilities",
"label": "New lease liabilities",
"terseLabel": "New lease liabilities"
}
}
},
"localname": "Newleaseliabilities",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/LeasesDetails"
],
"xbrltype": "monetaryItemType"
},
"esmc_OperatingLossCarryforwardExpirationPeriodAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Expiration period carryforward [Axis]",
"label": "Operating Loss Carryforward, Expiration Period [Axis]",
"terseLabel": "Operating Loss Carryforward, Expiration Period [Axis]"
}
}
},
"localname": "OperatingLossCarryforwardExpirationPeriodAxis",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails"
],
"xbrltype": "stringItemType"
},
"esmc_OperatingLossCarryforwardExpirationPeriodDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Operating Loss Carryforward, Expiration Period [Domain]",
"label": "Operating Loss Carryforward, Expiration Period [Domain]",
"terseLabel": "Operating Loss Carryforward, Expiration Period [Domain]"
}
}
},
"localname": "OperatingLossCarryforwardExpirationPeriodDomain",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails"
],
"xbrltype": "domainItemType"
},
"esmc_PPPloanamount": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "PPP loan amount",
"label": "PPP loan amount",
"terseLabel": "PPP loan amount"
}
}
},
"localname": "PPPloanamount",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtDetails",
"http://www.escalonmed.com/role/OrganizationandDescriptionofBusinessDetails"
],
"xbrltype": "monetaryItemType"
},
"esmc_PayrollProtectionProgramLoanMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Payroll Protection Program Loan [Member]",
"label": "Payroll Protection Program Loan [Member]",
"terseLabel": "Payroll Protection Program Loan [Member]"
}
}
},
"localname": "PayrollProtectionProgramLoanMember",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "domainItemType"
},
"esmc_PppLoanPolicyPolicyTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "PPP Loan Policy",
"label": "ppp loan policy [Policy Text Block]",
"terseLabel": "ppp loan policy"
}
}
},
"localname": "PppLoanPolicyPolicyTextBlock",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"esmc_RecordLeaseLiabilities": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"label": "Record lease liabilities",
"terseLabel": "Record lease liability per ASC 842"
}
}
},
"localname": "RecordLeaseLiabilities",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
],
"xbrltype": "monetaryItemType"
},
"esmc_RecordROUassets": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "RecordROUassets",
"label": "RecordROUassets",
"terseLabel": "Record right-of-use assets per ASC 842"
}
}
},
"localname": "RecordROUassets",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
],
"xbrltype": "monetaryItemType"
},
"esmc_RelatedPartyMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Related Party [Member]",
"label": "Related Party [Member]",
"terseLabel": "Related Party [Member]"
}
}
},
"localname": "RelatedPartyMember",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "domainItemType"
},
"esmc_RetirementBenefitObligationRollForward": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Retirement Benefit Obligation",
"label": "Retirement Benefit Obligation [Roll Forward]",
"terseLabel": "Retirement Benefit Obligation [Roll Forward]"
}
}
},
"localname": "RetirementBenefitObligationRollForward",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/RetirementandpostretirementplansliabilityrollforwardDetails"
],
"xbrltype": "stringItemType"
},
"esmc_ScheduleofinventoryAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "schedule of inventory [Abstract]",
"label": "schedule of inventory [Abstract]",
"terseLabel": "schedule of inventory [Abstract]"
}
}
},
"localname": "ScheduleofinventoryAbstract",
"nsuri": "http://www.escalonmed.com/20220630",
"xbrltype": "stringItemType"
},
"esmc_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePeriod": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Exercise Period",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Exercise Period",
"terseLabel": "Exercise period"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePeriod",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"esmc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of Employee Stock Option Plans",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans",
"terseLabel": "Number of Plans"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails"
],
"xbrltype": "integerItemType"
},
"esmc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardUnvested": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Share Based Compensation Arrangement by Share Based Payment Award, Unvested [Line Items]",
"label": "Share Based Compensation Arrangement by Share Based Payment Award, Unvested",
"terseLabel": "Share Based Compensation Arrangement by Share Based Payment Award, Unvested"
}
}
},
"localname": "ShareBasedCompensationArrangementbyShareBasedPaymentAwardUnvested",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails"
],
"xbrltype": "sharesItemType"
},
"esmc_SmallBusinessAssociationLoanMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Small Business Association Loan [Member]",
"label": "Small Business Association Loan [Member]",
"terseLabel": "Small Business Association Loan [Member]"
}
}
},
"localname": "SmallBusinessAssociationLoanMember",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "domainItemType"
},
"esmc_SupplierThreeMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Supplier three",
"label": "supplier three [Member]",
"terseLabel": "supplier three"
}
}
},
"localname": "SupplierThreeMember",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "domainItemType"
},
"esmc_SupplieroneMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Supplier one [Member]",
"label": "Supplier one [Member]",
"terseLabel": "Supplier one [Member]"
}
}
},
"localname": "SupplieroneMember",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "domainItemType"
},
"esmc_SuppliertwoMemberMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Supplier two [Member] [Member]",
"label": "Supplier two [Member] [Member]",
"terseLabel": "Supplier two [Member] [Member]"
}
}
},
"localname": "SuppliertwoMemberMember",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "domainItemType"
},
"esmc_Within24YearsDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Within 24 years [Domain]",
"label": "Within 24 years [Domain]",
"terseLabel": "Within 24 years [Domain]"
}
}
},
"localname": "Within24YearsDomain",
"nsuri": "http://www.escalonmed.com/20220630",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails"
],
"xbrltype": "domainItemType"
},
"srt_ConsolidationItemsAxis": {
"auth_ref": [
"r109",
"r168",
"r179",
"r180",
"r181",
"r182",
"r183",
"r185",
"r188",
"r270",
"r271",
"r272",
"r273",
"r274",
"r275",
"r277",
"r278",
"r280",
"r282",
"r283"
],
"lang": {
"en-us": {
"role": {
"label": "Consolidation Items [Axis]",
"terseLabel": "Consolidation Items [Axis]"
}
}
},
"localname": "ConsolidationItemsAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsTables"
],
"xbrltype": "stringItemType"
},
"srt_ConsolidationItemsDomain": {
"auth_ref": [
"r109",
"r168",
"r179",
"r180",
"r181",
"r182",
"r183",
"r185",
"r188",
"r270",
"r271",
"r272",
"r273",
"r274",
"r275",
"r277",
"r278",
"r280",
"r282",
"r283"
],
"lang": {
"en-us": {
"role": {
"label": "Consolidation Items [Domain]",
"terseLabel": "Consolidation Items [Domain]"
}
}
},
"localname": "ConsolidationItemsDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsTables"
],
"xbrltype": "domainItemType"
},
"srt_EquityMethodInvesteeNameDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Investment, Name [Domain]",
"terseLabel": "Equity Method Investee, Name [Domain]"
}
}
},
"localname": "EquityMethodInvesteeNameDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "domainItemType"
},
"srt_MajorCustomersAxis": {
"auth_ref": [
"r192",
"r347",
"r351",
"r550"
],
"lang": {
"en-us": {
"role": {
"label": "Customer [Axis]",
"terseLabel": "Customer [Axis]"
}
}
},
"localname": "MajorCustomersAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "stringItemType"
},
"srt_MaximumMember": {
"auth_ref": [
"r260",
"r261",
"r262",
"r263",
"r288",
"r321",
"r360",
"r362",
"r504",
"r505",
"r506",
"r507",
"r508",
"r509",
"r510",
"r547",
"r551",
"r578",
"r579"
],
"lang": {
"en-us": {
"role": {
"label": "Maximum [Member]",
"terseLabel": "Maximum [Member]"
}
}
},
"localname": "MaximumMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails",
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails",
"http://www.escalonmed.com/role/IntangibleassetsDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails"
],
"xbrltype": "domainItemType"
},
"srt_MinimumMember": {
"auth_ref": [
"r260",
"r261",
"r262",
"r263",
"r288",
"r321",
"r360",
"r362",
"r504",
"r505",
"r506",
"r507",
"r508",
"r509",
"r510",
"r547",
"r551",
"r578",
"r579"
],
"lang": {
"en-us": {
"role": {
"label": "Minimum [Member]",
"terseLabel": "Minimum [Member]"
}
}
},
"localname": "MinimumMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails",
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails",
"http://www.escalonmed.com/role/LineofcreditDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesStockBasedCompensationDetails"
],
"xbrltype": "domainItemType"
},
"srt_NameOfMajorCustomerDomain": {
"auth_ref": [
"r192",
"r347",
"r351",
"r550"
],
"lang": {
"en-us": {
"role": {
"label": "Customer [Domain]",
"terseLabel": "Customer [Domain]"
}
}
},
"localname": "NameOfMajorCustomerDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "domainItemType"
},
"srt_OwnershipAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Ownership [Axis]",
"terseLabel": "Ownership [Axis]"
}
}
},
"localname": "OwnershipAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "stringItemType"
},
"srt_OwnershipDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Ownership [Domain]",
"terseLabel": "Ownership [Domain]"
}
}
},
"localname": "OwnershipDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "domainItemType"
},
"srt_ProductOrServiceAxis": {
"auth_ref": [
"r189",
"r261",
"r262",
"r347",
"r349",
"r513",
"r546",
"r548"
],
"lang": {
"en-us": {
"role": {
"label": "Product and Service [Axis]",
"terseLabel": "Product and Service [Axis]"
}
}
},
"localname": "ProductOrServiceAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "stringItemType"
},
"srt_ProductsAndServicesDomain": {
"auth_ref": [
"r189",
"r261",
"r262",
"r347",
"r349",
"r513",
"r546",
"r548"
],
"lang": {
"en-us": {
"role": {
"label": "Product and Service [Domain]",
"terseLabel": "Product and Service [Domain]"
}
}
},
"localname": "ProductsAndServicesDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "domainItemType"
},
"srt_RangeAxis": {
"auth_ref": [
"r253",
"r260",
"r261",
"r262",
"r263",
"r288",
"r321",
"r358",
"r360",
"r362",
"r392",
"r393",
"r394",
"r504",
"r505",
"r506",
"r507",
"r508",
"r509",
"r510",
"r547",
"r551",
"r578",
"r579"
],
"lang": {
"en-us": {
"role": {
"label": "Statistical Measurement [Axis]",
"terseLabel": "Statistical Measurement [Axis]"
}
}
},
"localname": "RangeAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails",
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails",
"http://www.escalonmed.com/role/IntangibleassetsDetails",
"http://www.escalonmed.com/role/IntangibleassetsTables",
"http://www.escalonmed.com/role/LineofcreditDetails",
"http://www.escalonmed.com/role/LongtermDebtDetails",
"http://www.escalonmed.com/role/LongtermDebtEIDLmaturitiesTables",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentTables",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesStockBasedCompensationDetails"
],
"xbrltype": "stringItemType"
},
"srt_RangeMember": {
"auth_ref": [
"r253",
"r260",
"r261",
"r262",
"r263",
"r288",
"r321",
"r358",
"r360",
"r362",
"r392",
"r393",
"r394",
"r504",
"r505",
"r506",
"r507",
"r508",
"r509",
"r510",
"r547",
"r551",
"r578",
"r579"
],
"lang": {
"en-us": {
"role": {
"label": "Statistical Measurement [Domain]",
"terseLabel": "Statistical Measurement [Domain]"
}
}
},
"localname": "RangeMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails",
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails",
"http://www.escalonmed.com/role/IntangibleassetsDetails",
"http://www.escalonmed.com/role/IntangibleassetsTables",
"http://www.escalonmed.com/role/LineofcreditDetails",
"http://www.escalonmed.com/role/LongtermDebtDetails",
"http://www.escalonmed.com/role/LongtermDebtEIDLmaturitiesTables",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentTables",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesStockBasedCompensationDetails"
],
"xbrltype": "domainItemType"
},
"srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
"auth_ref": [
"r568",
"r569",
"r570",
"r571",
"r572",
"r573",
"r574",
"r575",
"r577"
],
"lang": {
"en-us": {
"role": {
"label": "Name of Property [Axis]",
"terseLabel": "Name of Property [Axis]"
}
}
},
"localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails"
],
"xbrltype": "stringItemType"
},
"srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
"auth_ref": [
"r568",
"r569",
"r570",
"r571",
"r572",
"r573",
"r574",
"r575",
"r577"
],
"lang": {
"en-us": {
"role": {
"label": "Name of Property [Domain]",
"terseLabel": "Name of Property [Domain]"
}
}
},
"localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails"
],
"xbrltype": "domainItemType"
},
"srt_RestatementAxis": {
"auth_ref": [
"r1",
"r112",
"r113",
"r114",
"r115",
"r116",
"r117",
"r118",
"r119",
"r120",
"r122",
"r123",
"r124",
"r125",
"r126",
"r127",
"r146",
"r206",
"r207",
"r425",
"r447",
"r448",
"r449",
"r450",
"r473",
"r491",
"r492",
"r552",
"r553",
"r554",
"r555",
"r556",
"r557",
"r558",
"r559",
"r560",
"r561"
],
"lang": {
"en-us": {
"role": {
"label": "Revision of Prior Period [Axis]",
"terseLabel": "Revision of Prior Period [Axis]"
}
}
},
"localname": "RestatementAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails"
],
"xbrltype": "stringItemType"
},
"srt_RestatementDomain": {
"auth_ref": [
"r1",
"r112",
"r113",
"r114",
"r115",
"r116",
"r117",
"r118",
"r119",
"r120",
"r122",
"r123",
"r124",
"r125",
"r126",
"r127",
"r146",
"r206",
"r207",
"r425",
"r447",
"r448",
"r449",
"r450",
"r473",
"r491",
"r492",
"r552",
"r553",
"r554",
"r555",
"r556",
"r557",
"r558",
"r559",
"r560",
"r561"
],
"lang": {
"en-us": {
"role": {
"label": "Revision of Prior Period [Domain]",
"terseLabel": "Revision of Prior Period [Domain]"
}
}
},
"localname": "RestatementDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails"
],
"xbrltype": "domainItemType"
},
"srt_ScenarioForecastMember": {
"auth_ref": [
"r121",
"r361"
],
"lang": {
"en-us": {
"role": {
"label": "Forecast [Member]",
"terseLabel": "Scenario, Forecast"
}
}
},
"localname": "ScenarioForecastMember",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsDetails"
],
"xbrltype": "domainItemType"
},
"srt_ScenarioUnspecifiedDomain": {
"auth_ref": [
"r121",
"r127",
"r259",
"r361"
],
"lang": {
"en-us": {
"role": {
"label": "Scenario [Domain]",
"terseLabel": "Scenario [Domain]"
}
}
},
"localname": "ScenarioUnspecifiedDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsDetails"
],
"xbrltype": "domainItemType"
},
"srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
"auth_ref": [
"r203"
],
"lang": {
"en-us": {
"role": {
"label": "Investment, Name [Axis]",
"terseLabel": "Equity Method Investee, Name [Axis]"
}
}
},
"localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "stringItemType"
},
"srt_SegmentGeographicalDomain": {
"auth_ref": [
"r190",
"r191",
"r347",
"r350",
"r549",
"r568",
"r569",
"r570",
"r571",
"r572",
"r573",
"r574",
"r575",
"r576"
],
"lang": {
"en-us": {
"role": {
"label": "Geographical [Domain]",
"terseLabel": "Geographical [Domain]"
}
}
},
"localname": "SegmentGeographicalDomain",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "domainItemType"
},
"srt_StatementGeographicalAxis": {
"auth_ref": [
"r190",
"r191",
"r347",
"r350",
"r549",
"r563",
"r568",
"r569",
"r570",
"r571",
"r572",
"r573",
"r574",
"r575",
"r576"
],
"lang": {
"en-us": {
"role": {
"label": "Geographical [Axis]",
"terseLabel": "Geographical [Axis]"
}
}
},
"localname": "StatementGeographicalAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "stringItemType"
},
"srt_StatementScenarioAxis": {
"auth_ref": [
"r121",
"r127",
"r259",
"r361",
"r503"
],
"lang": {
"en-us": {
"role": {
"label": "Scenario [Axis]",
"terseLabel": "Scenario [Axis]"
}
}
},
"localname": "StatementScenarioAxis",
"nsuri": "http://fasb.org/srt/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AccountingPoliciesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Accounting Policies [Abstract]",
"terseLabel": "Accounting Policies [Abstract]"
}
}
},
"localname": "AccountingPoliciesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
"label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
"terseLabel": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]"
}
}
},
"localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/AccruedexpenseNotes"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
"auth_ref": [
"r53"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
"label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
"terseLabel": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]"
}
}
},
"localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/AccruedexpenseNotes"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_AccountsPayableCurrent": {
"auth_ref": [
"r52",
"r502"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 5.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accounts Payable, Current",
"terseLabel": "Accounts payable"
}
}
},
"localname": "AccountsPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsReceivableMember": {
"auth_ref": [
"r564"
],
"lang": {
"en-us": {
"role": {
"documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
"label": "Accounts Receivable [Member]",
"terseLabel": "Accounts Receivable"
}
}
},
"localname": "AccountsReceivableMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccountsReceivableNetCurrent": {
"auth_ref": [
"r193",
"r194"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
"label": "Accounts Receivable, after Allowance for Credit Loss, Current",
"terseLabel": "Accounts receivable, net"
}
}
},
"localname": "AccountsReceivableNetCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedLiabilitiesCurrent": {
"auth_ref": [
"r57"
],
"calculation": {
"http://www.escalonmed.com/role/AccruedexpenseDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 6.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accrued Liabilities, Current",
"totalLabel": "Accrued Liabilities, Current",
"verboseLabel": "Accrued expenses"
}
}
},
"localname": "AccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/AccruedexpenseDetails",
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedRentCurrentAndNoncurrent": {
"auth_ref": [
"r26",
"r29",
"r520",
"r535"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements.",
"label": "Accrued Rent",
"terseLabel": "Accrued Rent"
}
}
},
"localname": "AccruedRentCurrentAndNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/AccruedexpenseDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
"auth_ref": [
"r20",
"r249"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
"label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
"negatedTerseLabel": "Less: Accumulated depreciation and amortization"
}
}
},
"localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapital": {
"auth_ref": [
"r36",
"r502"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
"label": "Additional Paid in Capital",
"terseLabel": "Additional paid-in capital"
}
}
},
"localname": "AdditionalPaidInCapital",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapitalMember": {
"auth_ref": [
"r112",
"r113",
"r114",
"r399",
"r400",
"r401",
"r448"
],
"lang": {
"en-us": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
"label": "Additional Paid-in Capital [Member]",
"terseLabel": "Additional Paid-in Capital [Member]"
}
}
},
"localname": "AdditionalPaidInCapitalMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.",
"label": "APIC, Share-Based Payment Arrangement, Recognition and Exercise",
"terseLabel": "APIC, Share-based Payment Arrangement, Recognition and Exercise"
}
}
},
"localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:"
}
}
},
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_AdvertisingCostsPolicyCapitalizedDirectResponseAdvertising": {
"auth_ref": [
"r219",
"r220"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for capitalizing direct response advertising costs, including a description of the qualifying activity and the types of costs capitalized, and the manner in which capitalized costs are recognized as expense and the basis for the timing thereof. The following amounts may also be disclosed: (1) total advertising costs reported as assets in each balance sheet presented and (2) any write-downs of capitalized advertising costs to net realizable value that are included in advertising expense.",
"label": "Advertising Costs, Policy, Capitalized Direct Response Advertising [Policy Text Block]",
"terseLabel": "Advertising Costs, Policy, Capitalized Direct Response Advertising [Policy Text Block]"
}
}
},
"localname": "AdvertisingCostsPolicyCapitalizedDirectResponseAdvertising",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_AdvertisingExpense": {
"auth_ref": [
"r402"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
"label": "Advertising Expense",
"terseLabel": "Advertising Expense"
}
}
},
"localname": "AdvertisingExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesadvertisingexpenseDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AllowanceForDoubtfulAccountsReceivable": {
"auth_ref": [
"r41",
"r199",
"r208",
"r209",
"r213"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of allowance for credit loss on accounts receivable.",
"label": "Accounts Receivable, Allowance for Credit Loss",
"terseLabel": "Accounts Receivable, Allowance for Credit Loss"
}
}
},
"localname": "AllowanceForDoubtfulAccountsReceivable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": {
"auth_ref": [
"r214"
],
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable.",
"label": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)",
"terseLabel": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)"
}
}
},
"localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
"auth_ref": [
"r212"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.",
"label": "Accounts Receivable, Allowance for Credit Loss, Recovery",
"negatedTerseLabel": "Accounts Receivable, Allowance for Credit Loss, Recovery"
}
}
},
"localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
"auth_ref": [
"r211"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
"label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
"negatedTerseLabel": "Accounts Receivable, Allowance for Credit Loss, Writeoff"
}
}
},
"localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
"auth_ref": [
"r144"
],
"lang": {
"en-us": {
"role": {
"documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
"terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
"auth_ref": [
"r144"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of antidilutive security.",
"label": "Antidilutive Securities [Axis]",
"terseLabel": "Antidilutive Securities [Axis]"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
"terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_AntidilutiveSecuritiesNameDomain": {
"auth_ref": [
"r144"
],
"lang": {
"en-us": {
"role": {
"documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
"label": "Antidilutive Securities, Name [Domain]",
"terseLabel": "Antidilutive Securities, Name [Domain]"
}
}
},
"localname": "AntidilutiveSecuritiesNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesTables"
],
"xbrltype": "domainItemType"
},
"us-gaap_Assets": {
"auth_ref": [
"r23",
"r104",
"r176",
"r181",
"r187",
"r204",
"r270",
"r271",
"r272",
"r274",
"r275",
"r276",
"r277",
"r279",
"r281",
"r283",
"r284",
"r441",
"r444",
"r457",
"r500",
"r502",
"r517",
"r534"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets",
"totalLabel": "Total assets"
}
}
},
"localname": "Assets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Assets [Abstract]",
"terseLabel": "ASSETS"
}
}
},
"localname": "AssetsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsCurrent": {
"auth_ref": [
"r12",
"r50",
"r104",
"r204",
"r270",
"r271",
"r272",
"r274",
"r275",
"r276",
"r277",
"r279",
"r281",
"r283",
"r284",
"r441",
"r444",
"r457",
"r500",
"r502"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets, Current",
"totalLabel": "Total current assets"
}
}
},
"localname": "AssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Assets, Current [Abstract]",
"terseLabel": "Current assets:"
}
}
},
"localname": "AssetsCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_AwardTypeAxis": {
"auth_ref": [
"r365",
"r366",
"r367",
"r369",
"r370",
"r371",
"r372",
"r373",
"r374",
"r375",
"r376",
"r377",
"r378",
"r379",
"r380",
"r381",
"r382",
"r385",
"r386",
"r388",
"r389",
"r391",
"r392",
"r393",
"r394",
"r395"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of award under share-based payment arrangement.",
"label": "Award Type [Axis]",
"terseLabel": "Award Type [Axis]"
}
}
},
"localname": "AwardTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsCompensationrelatedcostDetails",
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesStockBasedCompensationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"auth_ref": [
"r10",
"r18",
"r91"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
},
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlowsParenthetical": {
"order": 1.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash and Cash Equivalents, at Carrying Value",
"terseLabel": "Cash and cash equivalents, beginning of period",
"verboseLabel": "Cash and cash equivalents"
}
}
},
"localname": "CashAndCashEquivalentsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
"auth_ref": [
"r92"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
"label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
"terseLabel": "Cash and Cash Equivalents"
}
}
},
"localname": "CashAndCashEquivalentsPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
"auth_ref": [
"r83",
"r91",
"r95"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlowsParenthetical": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
"periodEndLabel": "Cash, cash equivalents and restricted cash, end of year",
"periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
"totalLabel": "Cash, cash equivalents and restricted cash"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows",
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
"terseLabel": "Cash, cash equivalents and restricted cash consist of the following:"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
],
"xbrltype": "stringItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
"auth_ref": [
"r83",
"r458"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
"totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Commitments and Contingencies Disclosure [Abstract]",
"terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
}
}
},
"localname": "CommitmentsAndContingenciesDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
"auth_ref": [
"r256",
"r257",
"r258",
"r264",
"r565"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for commitments and contingencies.",
"label": "Commitments and Contingencies Disclosure [Text Block]",
"terseLabel": "Commitments and Contingencies"
}
}
},
"localname": "CommitmentsAndContingenciesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CommitmentsandContingencies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CommonStockConversionBasis": {
"auth_ref": [
"r35"
],
"lang": {
"en-us": {
"role": {
"documentation": "Description of basis for conversion of convertible common stock.",
"label": "Common Stock, Conversion Basis",
"terseLabel": "Common Stock, Conversion Basis"
}
}
},
"localname": "CommonStockConversionBasis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CommonStockMember": {
"auth_ref": [
"r112",
"r113",
"r448"
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock that is subordinate to all other stock of the issuer.",
"label": "Common Stock [Member]",
"terseLabel": "Common Stock [Member]"
}
}
},
"localname": "CommonStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockParOrStatedValuePerShare": {
"auth_ref": [
"r35"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of common stock.",
"label": "Common Stock, Par or Stated Value Per Share",
"terseLabel": "Common stock, par value"
}
}
},
"localname": "CommonStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "perShareItemType"
},
"us-gaap_CommonStockSharesAuthorized": {
"auth_ref": [
"r35"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
"label": "Common Stock, Shares Authorized",
"terseLabel": "Common stock, shares authorized"
}
}
},
"localname": "CommonStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesIssued": {
"auth_ref": [
"r35"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
"label": "Common Stock, Shares, Issued",
"terseLabel": "Common stock, shares issued"
}
}
},
"localname": "CommonStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesOutstanding": {
"auth_ref": [
"r35",
"r335"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
"label": "Common Stock, Shares, Outstanding",
"verboseLabel": "Common stock, shares outstanding"
}
}
},
"localname": "CommonStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockValue": {
"auth_ref": [
"r35",
"r502"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Common Stock, Value, Issued",
"terseLabel": "Common stock, $0.001 par value; 35,000,000 shares authorized; 7,415,329 shares issued and outstanding"
}
}
},
"localname": "CommonStockValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommonStockVotingRights": {
"auth_ref": [
"r336"
],
"lang": {
"en-us": {
"role": {
"documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
"label": "Common Stock, Voting Rights",
"terseLabel": "Common Stock, Voting Rights"
}
}
},
"localname": "CommonStockVotingRights",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CompensationAndRetirementDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Retirement Benefits [Abstract]",
"terseLabel": "Retirement Benefits [Abstract]"
}
}
},
"localname": "CompensationAndRetirementDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskBenchmarkDomain": {
"auth_ref": [
"r158",
"r159",
"r192",
"r454",
"r455",
"r564"
],
"lang": {
"en-us": {
"role": {
"documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
"label": "Concentration Risk Benchmark [Domain]",
"terseLabel": "Concentration Risk Benchmark [Domain]"
}
}
},
"localname": "ConcentrationRiskBenchmarkDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails",
"http://www.escalonmed.com/role/ConcentrationofcreditriskNotes",
"http://www.escalonmed.com/role/ConcentrationofcreditriskTables"
],
"xbrltype": "domainItemType"
},
"us-gaap_ConcentrationRiskByBenchmarkAxis": {
"auth_ref": [
"r158",
"r159",
"r192",
"r454",
"r455",
"r562",
"r564"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by benchmark of concentration risk.",
"label": "Concentration Risk Benchmark [Axis]",
"terseLabel": "Concentration Risk Benchmark [Axis]"
}
}
},
"localname": "ConcentrationRiskByBenchmarkAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails",
"http://www.escalonmed.com/role/ConcentrationofcreditriskNotes",
"http://www.escalonmed.com/role/ConcentrationofcreditriskTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskByTypeAxis": {
"auth_ref": [
"r158",
"r159",
"r192",
"r454",
"r455",
"r562",
"r564"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
"label": "Concentration Risk Type [Axis]",
"terseLabel": "Concentration Risk Type [Axis]"
}
}
},
"localname": "ConcentrationRiskByTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails",
"http://www.escalonmed.com/role/ConcentrationofcreditriskNotes",
"http://www.escalonmed.com/role/ConcentrationofcreditriskTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskCustomer": {
"auth_ref": [
"r155",
"r156",
"r159"
],
"lang": {
"en-us": {
"role": {
"documentation": "Description of risks that arise due to the volume of business transacted with a particular customer. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes \"Information about Major Customers\" that may be disclosed elsewhere (for instance, segment disclosures).",
"label": "Concentration Risk, Customer",
"terseLabel": "Concentration Risk, Customer"
}
}
},
"localname": "ConcentrationRiskCustomer",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskDisclosureTextBlock": {
"auth_ref": [
"r165"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
"label": "Concentration Risk Disclosure [Text Block]",
"terseLabel": "Concentration Risk Disclosure [Text Block]"
}
}
},
"localname": "ConcentrationRiskDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskNotes"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ConcentrationRiskLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Concentration Risk [Line Items]",
"terseLabel": "Concentration Risk [Line Items]"
}
}
},
"localname": "ConcentrationRiskLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails",
"http://www.escalonmed.com/role/ConcentrationofcreditriskNotes",
"http://www.escalonmed.com/role/ConcentrationofcreditriskTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskPercentage1": {
"auth_ref": [
"r158",
"r159",
"r192",
"r454",
"r455"
],
"lang": {
"en-us": {
"role": {
"documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
"label": "Concentration Risk, Percentage",
"terseLabel": "Concentration Risk, Percentage"
}
}
},
"localname": "ConcentrationRiskPercentage1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ConcentrationRiskSupplier": {
"auth_ref": [
"r155",
"r156",
"r159",
"r164"
],
"lang": {
"en-us": {
"role": {
"documentation": "Description of risks that arise due to the volume of business transacted with a particular supplier or reliance placed on that supplier. At a minimum, the description informs financial statement users of the general nature of the risk.",
"label": "Concentration Risk, Supplier",
"terseLabel": "Concentration Risk, Supplier"
}
}
},
"localname": "ConcentrationRiskSupplier",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskTable": {
"auth_ref": [
"r155",
"r158",
"r159",
"r160",
"r454",
"r456",
"r564"
],
"lang": {
"en-us": {
"role": {
"documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
"label": "Concentration Risk [Table]",
"terseLabel": "Concentration Risk [Table]"
}
}
},
"localname": "ConcentrationRiskTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails",
"http://www.escalonmed.com/role/ConcentrationofcreditriskNotes",
"http://www.escalonmed.com/role/ConcentrationofcreditriskTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskTypeDomain": {
"auth_ref": [
"r158",
"r159",
"r192",
"r454",
"r455",
"r564"
],
"lang": {
"en-us": {
"role": {
"documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
"label": "Concentration Risk Type [Domain]",
"terseLabel": "Concentration Risk Type [Domain]"
}
}
},
"localname": "ConcentrationRiskTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails",
"http://www.escalonmed.com/role/ConcentrationofcreditriskNotes",
"http://www.escalonmed.com/role/ConcentrationofcreditriskTables"
],
"xbrltype": "domainItemType"
},
"us-gaap_ConsolidationPolicyTextBlock": {
"auth_ref": [
"r97",
"r443"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
"label": "Consolidation, Policy [Policy Text Block]",
"terseLabel": "Principles of Consolidation"
}
}
},
"localname": "ConsolidationPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ContractWithCustomerLiability": {
"auth_ref": [
"r344",
"r345",
"r348"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
"label": "Contract with Customer, Liability",
"terseLabel": "Contract with Customer, Liability"
}
}
},
"localname": "ContractWithCustomerLiability",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiabilityCurrent": {
"auth_ref": [
"r344",
"r345",
"r348"
],
"calculation": {
"http://www.escalonmed.com/role/AccruedexpenseDetails": {
"order": 5.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
"label": "Contract with Customer, Liability, Current",
"terseLabel": "Customer Deposits, Current"
}
}
},
"localname": "ContractWithCustomerLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/AccruedexpenseDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ConvertiblePreferredDividendsNetOfTax": {
"auth_ref": [
"r129",
"r130",
"r132",
"r142",
"r329"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The after-tax amount of any dividends on convertible preferred stock.",
"label": "Convertible Preferred Dividends, Net of Tax",
"terseLabel": "Convertible Preferred Dividends, Net of Tax"
}
}
},
"localname": "ConvertiblePreferredDividendsNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ConvertiblePreferredStockMember": {
"auth_ref": [
"r319",
"r320",
"r323"
],
"lang": {
"en-us": {
"role": {
"documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
"label": "Convertible Preferred Stock [Member]",
"terseLabel": "Convertible Preferred Stock [Member]"
}
}
},
"localname": "ConvertiblePreferredStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
"auth_ref": [
"r33",
"r34",
"r331",
"r336",
"r338"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
"label": "Convertible Preferred Stock, Shares Issued upon Conversion",
"terseLabel": "Convertible Preferred Stock, Shares Issued upon Conversion"
}
}
},
"localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CostOfGoodsAndServicesSold": {
"auth_ref": [
"r75",
"r513"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": {
"order": 3.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
"label": "Cost of Goods and Services Sold",
"terseLabel": "Cost of Goods and Services Sold"
}
}
},
"localname": "CostOfGoodsAndServicesSold",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CostsAndExpenses": {
"auth_ref": [
"r74"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": {
"order": 2.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Total costs of sales and operating expenses for the period.",
"label": "Costs and Expenses",
"totalLabel": "Total costs and expenses"
}
}
},
"localname": "CostsAndExpenses",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CostsAndExpensesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Costs and Expenses [Abstract]",
"terseLabel": "Costs and expenses:"
}
}
},
"localname": "CostsAndExpensesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "stringItemType"
},
"us-gaap_CreditFacilityAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
"label": "Credit Facility [Axis]",
"terseLabel": "Credit Facility [Axis]"
}
}
},
"localname": "CreditFacilityAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditDetails",
"http://www.escalonmed.com/role/LongtermDebtTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_CreditFacilityDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
"label": "Credit Facility [Domain]",
"terseLabel": "Credit Facility [Domain]"
}
}
},
"localname": "CreditFacilityDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditDetails",
"http://www.escalonmed.com/role/LongtermDebtTables"
],
"xbrltype": "domainItemType"
},
"us-gaap_CurrentFederalTaxExpenseBenefit": {
"auth_ref": [
"r105",
"r421",
"r427"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
"label": "Current Federal Tax Expense (Benefit)",
"terseLabel": "Current Federal Tax Expense (Benefit)"
}
}
},
"localname": "CurrentFederalTaxExpenseBenefit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CurrentIncomeTaxExpenseBenefit": {
"auth_ref": [
"r105",
"r421",
"r427",
"r429"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
"label": "Current Income Tax Expense (Benefit)",
"terseLabel": "Current Income Tax Expense (Benefit)"
}
}
},
"localname": "CurrentIncomeTaxExpenseBenefit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
"auth_ref": [
"r105",
"r421",
"r427"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
"label": "Current State and Local Tax Expense (Benefit)",
"terseLabel": "Current State and Local Tax Expense (Benefit)"
}
}
},
"localname": "CurrentStateAndLocalTaxExpenseBenefit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CustomerConcentrationRiskMember": {
"auth_ref": [
"r156",
"r192"
],
"lang": {
"en-us": {
"role": {
"documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
"label": "Customer Concentration Risk [Member]",
"terseLabel": "Customer Concentration Risk [Member]"
}
}
},
"localname": "CustomerConcentrationRiskMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CustomerDepositsCurrent": {
"auth_ref": [
"r57"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The current portion of money or property received from customers which is either to be returned upon satisfactory contract completion or applied to customer receivables in accordance with the terms of the contract or the understandings.",
"label": "Customer Deposits, Current",
"terseLabel": "Customer Deposits, Current"
}
}
},
"localname": "CustomerDepositsCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Debt Disclosure [Abstract]",
"terseLabel": "Debt Disclosure [Abstract]"
}
}
},
"localname": "DebtDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_DebtDisclosureTextBlock": {
"auth_ref": [
"r101",
"r291",
"r292",
"r293",
"r294",
"r295",
"r296",
"r297",
"r302",
"r309",
"r310",
"r312",
"r318"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
"label": "Debt Disclosure [Text Block]",
"terseLabel": "Debt Disclosure [Text Block]"
}
}
},
"localname": "DebtDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditNotes"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DebtInstrumentAxis": {
"auth_ref": [
"r25",
"r26",
"r27",
"r103",
"r109",
"r285",
"r286",
"r287",
"r288",
"r289",
"r290",
"r292",
"r298",
"r299",
"r300",
"r301",
"r303",
"r304",
"r305",
"r306",
"r307",
"r308",
"r314",
"r315",
"r316",
"r317",
"r470",
"r518",
"r522",
"r533"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
"label": "Debt Instrument [Axis]",
"terseLabel": "Debt Instrument [Axis]"
}
}
},
"localname": "DebtInstrumentAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtDetails",
"http://www.escalonmed.com/role/LongtermDebtEIDLmaturitiesTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
"label": "Debt Instrument, Basis Spread on Variable Rate",
"terseLabel": "Debt Instrument, Basis Spread on Variable Rate"
}
}
},
"localname": "DebtInstrumentBasisSpreadOnVariableRate1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentInterestRateDuringPeriod": {
"auth_ref": [
"r59",
"r305",
"r468"
],
"lang": {
"en-us": {
"role": {
"documentation": "The average effective interest rate during the reporting period.",
"label": "Debt Instrument, Interest Rate During Period",
"terseLabel": "Debt Instrument, Interest Rate During Period"
}
}
},
"localname": "DebtInstrumentInterestRateDuringPeriod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentInterestRateStatedPercentage": {
"auth_ref": [
"r59",
"r286"
],
"lang": {
"en-us": {
"role": {
"documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
"label": "Debt Instrument, Interest Rate, Stated Percentage",
"terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
}
}
},
"localname": "DebtInstrumentInterestRateStatedPercentage",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Debt Instrument [Line Items]",
"terseLabel": "Debt Instrument [Line Items]"
}
}
},
"localname": "DebtInstrumentLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtDetails",
"http://www.escalonmed.com/role/LongtermDebtEIDLmaturitiesTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentNameDomain": {
"auth_ref": [
"r60",
"r103",
"r109",
"r285",
"r286",
"r287",
"r288",
"r289",
"r290",
"r292",
"r298",
"r299",
"r300",
"r301",
"r303",
"r304",
"r305",
"r306",
"r307",
"r308",
"r314",
"r315",
"r316",
"r317",
"r470"
],
"lang": {
"en-us": {
"role": {
"documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
"label": "Debt Instrument, Name [Domain]",
"terseLabel": "Debt Instrument, Name [Domain]"
}
}
},
"localname": "DebtInstrumentNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtDetails",
"http://www.escalonmed.com/role/LongtermDebtEIDLmaturitiesTables"
],
"xbrltype": "domainItemType"
},
"us-gaap_DebtInstrumentRedemptionPeriodAxis": {
"auth_ref": [
"r530"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
"label": "Debt Instrument, Redemption, Period [Axis]",
"terseLabel": "Debt Instrument, Redemption, Period [Axis]"
}
}
},
"localname": "DebtInstrumentRedemptionPeriodAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtDetails",
"http://www.escalonmed.com/role/LongtermDebtEIDLmaturitiesTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentRedemptionPeriodDomain": {
"auth_ref": [
"r530"
],
"lang": {
"en-us": {
"role": {
"documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
"label": "Debt Instrument, Redemption, Period [Domain]",
"terseLabel": "Debt Instrument, Redemption, Period [Domain]"
}
}
},
"localname": "DebtInstrumentRedemptionPeriodDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtDetails",
"http://www.escalonmed.com/role/LongtermDebtEIDLmaturitiesTables"
],
"xbrltype": "domainItemType"
},
"us-gaap_DebtInstrumentTable": {
"auth_ref": [
"r60",
"r103",
"r109",
"r285",
"r286",
"r287",
"r288",
"r289",
"r290",
"r292",
"r298",
"r299",
"r300",
"r301",
"r303",
"r304",
"r305",
"r306",
"r307",
"r308",
"r311",
"r314",
"r315",
"r316",
"r317",
"r336",
"r339",
"r340",
"r341",
"r467",
"r468",
"r470",
"r471",
"r531"
],
"lang": {
"en-us": {
"role": {
"documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
"label": "Schedule of Long-Term Debt Instruments [Table]",
"terseLabel": "Schedule of Long-term Debt Instruments [Table]"
}
}
},
"localname": "DebtInstrumentTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtDetails",
"http://www.escalonmed.com/role/LongtermDebtEIDLmaturitiesTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
"auth_ref": [
"r105",
"r422",
"r427"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
"label": "Deferred Federal Income Tax Expense (Benefit)",
"terseLabel": "Deferred Federal Income Tax Expense (Benefit)"
}
}
},
"localname": "DeferredFederalIncomeTaxExpenseBenefit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredIncomeTaxExpenseBenefit": {
"auth_ref": [
"r89",
"r105",
"r422",
"r427",
"r428",
"r429"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
"label": "Deferred Income Tax Expense (Benefit)",
"terseLabel": "Deferred Income Tax Expense (Benefit)"
}
}
},
"localname": "DeferredIncomeTaxExpenseBenefit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredIncomeTaxLiabilities": {
"auth_ref": [
"r30",
"r31",
"r411",
"r519",
"r532"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
"label": "Deferred Tax Liabilities, Gross",
"negatedTerseLabel": "Deferred Tax Liabilities, Gross"
}
}
},
"localname": "DeferredIncomeTaxLiabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredRevenue": {
"auth_ref": [
"r32"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
"label": "Deferred Revenue",
"terseLabel": "Deferred Revenue"
}
}
},
"localname": "DeferredRevenue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredRevenueAdditions": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.",
"label": "Deferred Revenue, Additions",
"terseLabel": "Deferred Revenue, Additions"
}
}
},
"localname": "DeferredRevenueAdditions",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.",
"label": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]",
"terseLabel": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]"
}
}
},
"localname": "DeferredRevenueByArrangementDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesDeferredrevenueTables",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DeferredRevenueCurrent": {
"auth_ref": [
"r26"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 9.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
"label": "Deferred Revenue, Current",
"terseLabel": "Deferred Revenue, Current"
}
}
},
"localname": "DeferredRevenueCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredRevenueRevenueRecognized1": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.",
"label": "Deferred Revenue, Revenue Recognized",
"negatedTerseLabel": "Deferred Revenue, Revenue Recognized"
}
}
},
"localname": "DeferredRevenueRevenueRecognized1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesdeferredrevenueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
"auth_ref": [
"r105",
"r422",
"r427"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
"label": "Deferred State and Local Income Tax Expense (Benefit)",
"terseLabel": "Deferred State and Local Income Tax Expense (Benefit)"
}
}
},
"localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredTaxAssetsGross": {
"auth_ref": [
"r412"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
"label": "Deferred Tax Assets, Gross",
"terseLabel": "Deferred Tax Assets, Gross"
}
}
},
"localname": "DeferredTaxAssetsGross",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredTaxAssetsLiabilitiesNet": {
"auth_ref": [
"r414"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
"label": "Deferred Tax Assets, Net",
"terseLabel": "Deferred Tax Assets, Net"
}
}
},
"localname": "DeferredTaxAssetsLiabilitiesNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredTaxAssetsNet": {
"auth_ref": [
"r414"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
"label": "Deferred Tax Assets, Net of Valuation Allowance",
"terseLabel": "Deferred Tax Assets, Net of Valuation Allowance"
}
}
},
"localname": "DeferredTaxAssetsNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
"auth_ref": [
"r419",
"r420"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
"label": "Deferred Tax Assets, Operating Loss Carryforwards",
"terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards"
}
}
},
"localname": "DeferredTaxAssetsOperatingLossCarryforwards",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
"label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
"terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration"
}
}
},
"localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails",
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
"label": "Deferred Tax Assets, Property, Plant and Equipment",
"terseLabel": "Deferred Tax Assets, Property, Plant and Equipment"
}
}
},
"localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness": {
"auth_ref": [
"r417",
"r419",
"r420"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.",
"label": "Deferred Tax Assets, Tax Credit Carryforwards, General Business",
"terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, General Business"
}
}
},
"localname": "DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": {
"auth_ref": [
"r419",
"r420"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.",
"label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits",
"terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits"
}
}
},
"localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits": {
"auth_ref": [
"r419"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from postretirement benefits.",
"label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Postretirement Benefits",
"terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Postretirement Benefits"
}
}
},
"localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
"auth_ref": [
"r419",
"r420"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.",
"label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
"terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts"
}
}
},
"localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves": {
"auth_ref": [
"r419",
"r420"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.",
"label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves",
"terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves"
}
}
},
"localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves": {
"auth_ref": [
"r419",
"r420"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warranty reserves.",
"label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves",
"terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves"
}
}
},
"localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredTaxAssetsValuationAllowance": {
"auth_ref": [
"r413"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
"label": "Deferred Tax Assets, Valuation Allowance",
"negatedTerseLabel": "Deferred Tax Assets, Valuation Allowance",
"terseLabel": "Deferred Tax Assets, Valuation Allowance"
}
}
},
"localname": "DeferredTaxAssetsValuationAllowance",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails",
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredTaxLiabilitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Deferred Tax Liabilities, Gross [Abstract]",
"terseLabel": "Deferred income tax liabilities:"
}
}
},
"localname": "DeferredTaxLiabilitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
"auth_ref": [
"r419",
"r420"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
"label": "Deferred Tax Liabilities, Property, Plant and Equipment",
"negatedTerseLabel": "Deferred Tax Liabilities, Property, Plant and Equipment"
}
}
},
"localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
"auth_ref": [
"r359"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
"label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
"terseLabel": "Discount rate (percent)"
}
}
},
"localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/RetirementandpostretirementplansDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DepositsAssetsNoncurrent": {
"auth_ref": [
"r22"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 5.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
"label": "Deposits Assets, Noncurrent",
"terseLabel": "Deposits Assets, Noncurrent"
}
}
},
"localname": "DepositsAssetsNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DepreciationDepletionAndAmortization": {
"auth_ref": [
"r89",
"r171"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": 12.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
"label": "Depreciation, Depletion and Amortization",
"terseLabel": "Depreciation and amortization"
}
}
},
"localname": "DepreciationDepletionAndAmortization",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.",
"label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities",
"terseLabel": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities"
}
}
},
"localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DividendsPayableAmountPerShare": {
"auth_ref": [
"r94"
],
"lang": {
"en-us": {
"role": {
"documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.",
"label": "Dividends Payable, Amount Per Share",
"terseLabel": "Dividends Payable, Amount Per Share"
}
}
},
"localname": "DividendsPayableAmountPerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_DueToRelatedPartiesCurrent": {
"auth_ref": [
"r52",
"r108",
"r273",
"r275",
"r276",
"r282",
"r283",
"r284",
"r495"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 7.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Due to Related Parties, Current",
"terseLabel": "Due to Related Parties, Current"
}
}
},
"localname": "DueToRelatedPartiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EarningsPerShareAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share [Abstract]",
"terseLabel": "Net income (loss) per share"
}
}
},
"localname": "EarningsPerShareAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareBasic": {
"auth_ref": [
"r72",
"r117",
"r118",
"r120",
"r121",
"r122",
"r128",
"r131",
"r140",
"r141",
"r142",
"r146",
"r147",
"r449",
"r450",
"r526",
"r545"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
"label": "Earnings Per Share, Basic",
"terseLabel": "Earnings (Loss) Per Share, Basic"
}
}
},
"localname": "EarningsPerShareBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerShareDiluted": {
"auth_ref": [
"r72",
"r117",
"r118",
"r120",
"r121",
"r122",
"r131",
"r140",
"r141",
"r142",
"r146",
"r147",
"r449",
"r450",
"r526",
"r545"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
"label": "Earnings Per Share, Diluted",
"terseLabel": "Earnings (Loss) Per Share, Diluted",
"verboseLabel": "Earnings (Loss) Per Share, Diluted"
}
}
},
"localname": "EarningsPerShareDiluted",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerSharePolicyTextBlock": {
"auth_ref": [
"r144",
"r145"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
"label": "Earnings Per Share, Policy [Policy Text Block]",
"terseLabel": "Net Income (loss) Per Share"
}
}
},
"localname": "EarningsPerSharePolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
"auth_ref": [
"r406"
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
"label": "Effective Income Tax Rate Reconciliation, Percent",
"terseLabel": "Effective Income Tax Rate Reconciliation, Percent"
}
}
},
"localname": "EffectiveIncomeTaxRateContinuingOperations",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
"auth_ref": [
"r107",
"r406",
"r431"
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
"label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
"terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent"
}
}
},
"localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
"auth_ref": [
"r406",
"r431"
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
"label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
"negatedTerseLabel": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent"
}
}
},
"localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": {
"auth_ref": [
"r406",
"r431"
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.",
"label": "Effective Income Tax Rate Reconciliation, Deduction, Percent",
"terseLabel": "Effective Income Tax Rate Reconciliation, Deduction, Percent"
}
}
},
"localname": "EffectiveIncomeTaxRateReconciliationDeductions",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesEffectiveIncomeTaxRateDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_EmployeeRelatedLiabilitiesCurrent": {
"auth_ref": [
"r57"
],
"calculation": {
"http://www.escalonmed.com/role/AccruedexpenseDetails": {
"order": 6.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Employee-related Liabilities, Current",
"terseLabel": "Employee-related Liabilities, Current"
}
}
},
"localname": "EmployeeRelatedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/AccruedexpenseDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeStockOptionMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
"label": "Share-Based Payment Arrangement, Option [Member]",
"terseLabel": "Share-based Payment Arrangement, Option [Member]"
}
}
},
"localname": "EmployeeStockOptionMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Revenue from External Customer [Line Items]",
"terseLabel": "Revenue from External Customer [Line Items]"
}
}
},
"localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "stringItemType"
},
"us-gaap_EquipmentMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Tangible personal property used to produce goods and services.",
"label": "Equipment [Member]",
"terseLabel": "Equipment [Member]"
}
}
},
"localname": "EquipmentMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EquityComponentDomain": {
"auth_ref": [
"r0",
"r66",
"r67",
"r68",
"r112",
"r113",
"r114",
"r116",
"r123",
"r126",
"r149",
"r205",
"r335",
"r342",
"r399",
"r400",
"r401",
"r424",
"r425",
"r448",
"r459",
"r460",
"r461",
"r462",
"r463",
"r464",
"r492",
"r552",
"r553",
"r554"
],
"lang": {
"en-us": {
"role": {
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
"label": "Equity Component [Domain]",
"terseLabel": "Total Shareholders' Equity [Domain]",
"verboseLabel": "Equity Component [Domain]"
}
}
},
"localname": "EquityComponentDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails",
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails",
"http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss"
],
"xbrltype": "domainItemType"
},
"us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
"auth_ref": [
"r8",
"r104",
"r204",
"r457"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
"label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
"terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
}
}
},
"localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
"auth_ref": [
"r8",
"r104",
"r204",
"r457"
],
"lang": {
"en-us": {
"role": {
"documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
"label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
"terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
}
}
},
"localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": {
"auth_ref": [
"r8",
"r104",
"r204",
"r457"
],
"lang": {
"en-us": {
"role": {
"documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity.",
"label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]",
"terseLabel": "Equity Method Investment, Nonconsolidated Investee or Group of Investees"
}
}
},
"localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueOfFinancialInstrumentsPolicy": {
"auth_ref": [
"r451",
"r452"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
"label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
"terseLabel": "Fair Value of Financial Instruments"
}
}
},
"localname": "FairValueOfFinancialInstrumentsPolicy",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
"auth_ref": [
"r485"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Finance Lease, Liability, to be Paid, Year Five",
"terseLabel": "Finance Lease, Liability, to be Paid, Year Five"
}
}
},
"localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LeasesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
"auth_ref": [
"r485"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Finance Lease, Liability, to be Paid, Year Four",
"terseLabel": "Finance Lease, Liability, to be Paid, Year Four"
}
}
},
"localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LeasesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
"auth_ref": [
"r485"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Finance Lease, Liability, to be Paid, Year Three",
"terseLabel": "Finance Lease, Liability, to be Paid, Year Three"
}
}
},
"localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LeasesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
"auth_ref": [
"r485"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Finance Lease, Liability, to be Paid, Year Two",
"terseLabel": "Finance Lease, Liability, to be Paid, Year Two"
}
}
},
"localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LeasesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "Finite-Lived Intangible Asset, Useful Life",
"terseLabel": "Finite-Lived Intangible Asset, Useful Life"
}
}
},
"localname": "FiniteLivedIntangibleAssetUsefulLife",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
"auth_ref": [
"r21",
"r238"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
"label": "Finite-Lived Intangible Assets, Accumulated Amortization",
"negatedTerseLabel": "Amortized Intangible Assets Licenses"
}
}
},
"localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
"terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five"
}
}
},
"localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
"label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five",
"terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five"
}
}
},
"localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
"label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two",
"terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two"
}
}
},
"localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
"auth_ref": [
"r239"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
"terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Five"
}
}
},
"localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
"auth_ref": [
"r239"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
"terseLabel": "Finite-Lived Intangible Asset, Expected Amortization, Year Two"
}
}
},
"localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod": {
"auth_ref": [
"r233"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amortization method of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar either by their nature or by their use in the operations of a company. The straight-line method is the preferred amortization method, unless another method better reflects the pattern in which the asset is consumed.",
"label": "Finite-Lived Intangible Assets, Amortization Method",
"terseLabel": "Finite-Lived Intangible Assets, Amortization Method"
}
}
},
"localname": "FiniteLivedIntangibleAssetsAmortizationMethod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
"auth_ref": [
"r234",
"r235",
"r238",
"r241",
"r514",
"r515"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by major type or class of finite-lived intangible assets.",
"label": "Finite-Lived Intangible Assets by Major Class [Axis]",
"terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
}
}
},
"localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails",
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"http://www.escalonmed.com/role/IntangibleassetsDetails",
"http://www.escalonmed.com/role/IntangibleassetsTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsGross": {
"auth_ref": [
"r238",
"r515"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
"label": "Finite-Lived Intangible Assets, Gross",
"terseLabel": "Finite-Lived Intangible Assets, Gross"
}
}
},
"localname": "FiniteLivedIntangibleAssetsGross",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Finite-Lived Intangible Assets [Line Items]",
"terseLabel": "Finite-Lived Intangible Assets [Line Items]"
}
}
},
"localname": "FiniteLivedIntangibleAssetsLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
"auth_ref": [
"r234",
"r237"
],
"lang": {
"en-us": {
"role": {
"documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
"label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
"terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
}
}
},
"localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails",
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"http://www.escalonmed.com/role/IntangibleassetsDetails",
"http://www.escalonmed.com/role/IntangibleassetsTables"
],
"xbrltype": "domainItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsNet": {
"auth_ref": [
"r238",
"r514"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
"label": "Finite-Lived Intangible Assets, Net",
"terseLabel": "Finite-Lived Intangible Assets, Net"
}
}
},
"localname": "FiniteLivedIntangibleAssetsNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"http://www.escalonmed.com/role/IntangibleassetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
"auth_ref": [
"r465"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
"label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
"terseLabel": "Foreign Currency Transactions and Translations Policy [Policy Text Block]"
}
}
},
"localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FurnitureAndFixturesGross": {
"auth_ref": [
"r248"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
"label": "Furniture and Fixtures, Gross",
"terseLabel": "Furniture and fixtures"
}
}
},
"localname": "FurnitureAndFixturesGross",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FurnitureAndFixturesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
"label": "Furniture and Fixtures [Member]",
"terseLabel": "Furniture and Fixtures [Member]"
}
}
},
"localname": "FurnitureAndFixturesMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_GainLossOnContractTermination": {
"auth_ref": [
"r90"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.",
"label": "Gain (Loss) on Contract Termination",
"negatedLabel": "Actuarial adjustment",
"terseLabel": "Gain on termination of retirement benefit obligation"
}
}
},
"localname": "GainLossOnContractTermination",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/RetirementandpostretirementplansDetails",
"http://www.escalonmed.com/role/RetirementandpostretirementplansliabilityrollforwardDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GeographicConcentrationRiskMember": {
"auth_ref": [
"r157",
"r564"
],
"lang": {
"en-us": {
"role": {
"documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
"label": "Geographic Concentration Risk [Member]",
"terseLabel": "Geographic Concentration Risk [Member]"
}
}
},
"localname": "GeographicConcentrationRiskMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Goodwill and Intangible Assets Disclosure [Abstract]",
"terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
}
}
},
"localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
"auth_ref": [
"r230",
"r236"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
"label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
"terseLabel": "Intangible Assets"
}
}
},
"localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_GoodwillImpairmentLoss": {
"auth_ref": [
"r89",
"r221",
"r226",
"r231",
"r232"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
"label": "Goodwill, Impairment Loss",
"terseLabel": "Goodwill, Impairment Loss"
}
}
},
"localname": "GoodwillImpairmentLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesGoodwillandintangibleassetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
"auth_ref": [
"r89",
"r242"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
"label": "Impairment of Intangible Assets (Excluding Goodwill)",
"terseLabel": "Impairment of Intangible Assets (Excluding Goodwill)"
}
}
},
"localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesGoodwillandintangibleassetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
"auth_ref": [
"r106",
"r430"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
"label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
"terseLabel": "Income (Loss) from Continuing Operations before Income Taxes, Foreign"
}
}
},
"localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeStatementAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Income Statement [Abstract]",
"terseLabel": "Income Statement [Abstract]"
}
}
},
"localname": "IncomeStatementAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeTaxAuthorityAxis": {
"auth_ref": [
"r408"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by tax jurisdiction.",
"label": "Income Tax Authority [Axis]",
"terseLabel": "Income Tax Authority [Axis]"
}
}
},
"localname": "IncomeTaxAuthorityAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeTaxAuthorityDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
"label": "Income Tax Authority [Domain]",
"terseLabel": "Income Tax Authority [Domain]"
}
}
},
"localname": "IncomeTaxAuthorityDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeTaxDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Income Tax Disclosure [Abstract]",
"terseLabel": "Income Tax Disclosure [Abstract]"
}
}
},
"localname": "IncomeTaxDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeTaxDisclosureTextBlock": {
"auth_ref": [
"r107",
"r407",
"r409",
"r416",
"r426",
"r432",
"r433",
"r434",
"r435"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
"label": "Income Tax Disclosure [Text Block]",
"terseLabel": "Income Tax Disclosure [Text Block]"
}
}
},
"localname": "IncomeTaxDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxes"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_IncomeTaxPolicyTextBlock": {
"auth_ref": [
"r65",
"r404",
"r405",
"r409",
"r410",
"r415",
"r423"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
"label": "Income Tax, Policy [Policy Text Block]",
"terseLabel": "Income Taxes"
}
}
},
"localname": "IncomeTaxPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_IncomeTaxesPaid": {
"auth_ref": [
"r85",
"r93"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
"label": "Income Taxes Paid",
"terseLabel": "Income Taxes Paid"
}
}
},
"localname": "IncomeTaxesPaid",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccountsPayable": {
"auth_ref": [
"r88"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
"label": "Increase (Decrease) in Accounts Payable",
"terseLabel": "Accounts payable"
}
}
},
"localname": "IncreaseDecreaseInAccountsPayable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccountsReceivable": {
"auth_ref": [
"r88"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": 11.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
"label": "Increase (Decrease) in Accounts Receivable",
"negatedTerseLabel": "Accounts receivable"
}
}
},
"localname": "IncreaseDecreaseInAccountsReceivable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccruedLiabilities": {
"auth_ref": [
"r88"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
"label": "Increase (Decrease) in Accrued Liabilities",
"terseLabel": "Accrued expenses"
}
}
},
"localname": "IncreaseDecreaseInAccruedLiabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInDeferredRevenue": {
"auth_ref": [
"r88"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
"label": "Increase (Decrease) in Deferred Revenue",
"terseLabel": "Deferred revenue"
}
}
},
"localname": "IncreaseDecreaseInDeferredRevenue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInInventories": {
"auth_ref": [
"r88"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
"label": "Increase (Decrease) in Inventories",
"negatedTerseLabel": "Inventories"
}
}
},
"localname": "IncreaseDecreaseInInventories",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Increase (Decrease) in Operating Capital [Abstract]",
"terseLabel": "Change in operating assets and liabilities:"
}
}
},
"localname": "IncreaseDecreaseInOperatingCapitalAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
"auth_ref": [
"r88",
"r481"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": 13.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in obligation for operating lease.",
"label": "Increase (Decrease) in Operating Lease Liability",
"terseLabel": "Change in operating lease liability"
}
}
},
"localname": "IncreaseDecreaseInOperatingLeaseLiability",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
"auth_ref": [
"r88"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": 8.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in current assets classified as other.",
"label": "Increase (Decrease) in Other Current Assets",
"negatedTerseLabel": "Other current assets"
}
}
},
"localname": "IncreaseDecreaseInOtherCurrentAssets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOtherDeferredLiability": {
"auth_ref": [
"r88"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": 10.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in deferred obligations classified as other.",
"label": "Increase (Decrease) in Other Deferred Liability",
"terseLabel": "Other short-term and long-term liabilities"
}
}
},
"localname": "IncreaseDecreaseInOtherDeferredLiability",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": {
"auth_ref": [
"r136",
"r137",
"r142"
],
"calculation": {
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails": {
"order": 2.0,
"parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.",
"label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock",
"terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock"
}
}
},
"localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
"auth_ref": [
"r240"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
"label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
"verboseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)"
}
}
},
"localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IntangibleAssetsDisclosureTextBlock": {
"auth_ref": [
"r244"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for all or part of the information related to intangible assets.",
"label": "Intangible Assets Disclosure [Text Block]",
"terseLabel": "Intangible Assets Disclosure [Text Block]"
}
}
},
"localname": "IntangibleAssetsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsNotes"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_InterestExpense": {
"auth_ref": [
"r69",
"r170",
"r466",
"r469",
"r527"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": {
"order": 3.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
"label": "Interest Expense",
"negatedTerseLabel": "Interest expense"
}
}
},
"localname": "InterestExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestPaidNet": {
"auth_ref": [
"r82",
"r84",
"r93"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
"label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
"terseLabel": "Interest paid"
}
}
},
"localname": "InterestPaidNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestPayableCurrentAndNoncurrent": {
"auth_ref": [
"r524",
"r543"
],
"calculation": {
"http://www.escalonmed.com/role/AccruedexpenseDetails": {
"order": 3.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
"label": "Interest Payable",
"terseLabel": "Interest Payable"
}
}
},
"localname": "InterestPayableCurrentAndNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/AccruedexpenseDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InternalRevenueServiceIRSMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
"label": "Internal Revenue Service (IRS) [Member]",
"terseLabel": "Internal Revenue Service (IRS) [Member]"
}
}
},
"localname": "InternalRevenueServiceIRSMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_InventoryFinishedGoods": {
"auth_ref": [
"r42"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
"label": "Inventory, Finished Goods, Gross",
"terseLabel": "Inventory, Finished Goods, Gross"
}
}
},
"localname": "InventoryFinishedGoods",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesInventoryDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryGross": {
"auth_ref": [
"r48"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
"label": "Inventory, Gross",
"terseLabel": "Inventory, Gross"
}
}
},
"localname": "InventoryGross",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesInventoryDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryNet": {
"auth_ref": [
"r11",
"r48",
"r502"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
"label": "Inventory, Net",
"terseLabel": "Inventory, net"
}
}
},
"localname": "InventoryNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesInventoryDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryPolicyTextBlock": {
"auth_ref": [
"r14",
"r46",
"r98",
"r148",
"r215",
"r216",
"r218",
"r511"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
"label": "Inventory, Policy [Policy Text Block]",
"terseLabel": "Inventory"
}
}
},
"localname": "InventoryPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_InventoryRawMaterials": {
"auth_ref": [
"r44"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
"label": "Inventory, Raw Materials, Gross",
"terseLabel": "Inventory, Raw Materials, Gross"
}
}
},
"localname": "InventoryRawMaterials",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesInventoryDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryValuationReserves": {
"auth_ref": [
"r48",
"r217"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of valuation reserve for inventory.",
"label": "Inventory Valuation Reserves",
"negatedTerseLabel": "Inventory Valuation Reserves"
}
}
},
"localname": "InventoryValuationReserves",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesInventoryDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryWorkInProcess": {
"auth_ref": [
"r43"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
"label": "Inventory, Work in Process, Gross",
"terseLabel": "Inventory, Work in Process, Gross"
}
}
},
"localname": "InventoryWorkInProcess",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesInventoryDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InvestmentIncomeInterest": {
"auth_ref": [
"r77",
"r169"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": {
"order": 2.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
"label": "Investment Income, Interest",
"terseLabel": "Interest income"
}
}
},
"localname": "InvestmentIncomeInterest",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LeaseCostTableTextBlock": {
"auth_ref": [
"r484"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
"label": "Lease, Cost [Table Text Block]",
"terseLabel": "Lease, Cost [Table Text Block]"
}
}
},
"localname": "LeaseCostTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LeasesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LeaseholdImprovementsGross": {
"auth_ref": [
"r248"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
"label": "Leasehold Improvements, Gross",
"terseLabel": "Leasehold improvement"
}
}
},
"localname": "LeaseholdImprovementsGross",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LeaseholdImprovementsMember": {
"auth_ref": [
"r248"
],
"lang": {
"en-us": {
"role": {
"documentation": "Additions or improvements to assets held under a lease arrangement.",
"label": "Leasehold Improvements [Member]",
"terseLabel": "Leasehold Improvements [Member]"
}
}
},
"localname": "LeaseholdImprovementsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_LeasesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Leases [Abstract]",
"terseLabel": "Leases [Abstract]"
}
}
},
"localname": "LeasesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_LeasesOfLesseeDisclosureTextBlock": {
"auth_ref": [
"r472"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
"label": "Leases of Lessee Disclosure [Text Block]",
"terseLabel": "Leases of Lessee Disclosure [Text Block]"
}
}
},
"localname": "LeasesOfLesseeDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LeasesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LesseeLeasesPolicyTextBlock": {
"auth_ref": [
"r479"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
"label": "Lessee, Leases [Policy Text Block]",
"terseLabel": "Lessee, Leases [Policy Text Block]"
}
}
},
"localname": "LesseeLeasesPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
"auth_ref": [
"r485"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
"label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
"terseLabel": "Lessee, Operating Lease, Liability, Maturity"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LeasesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
"auth_ref": [
"r485"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
"label": "Lessee, Operating Lease, Liability, to be Paid",
"verboseLabel": "Operating Leases, Future Minimum Payments Due"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LeasesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseTermOfContract": {
"auth_ref": [
"r480"
],
"lang": {
"en-us": {
"role": {
"documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Lessee, Operating Lease, Term of Contract",
"terseLabel": "Lessee, Operating Lease, Term of Contract"
}
}
},
"localname": "LesseeOperatingLeaseTermOfContract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LeasesDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_LesseeOperatingLeasesTextBlock": {
"auth_ref": [
"r487"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
"label": "Lessee, Operating Leases [Text Block]",
"terseLabel": "Lessee, Operating Leases"
}
}
},
"localname": "LesseeOperatingLeasesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LeasesNotes"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LessorOperatingLeaseTermOfContract": {
"auth_ref": [
"r488"
],
"lang": {
"en-us": {
"role": {
"documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Lessor, Operating Lease, Term of Contract",
"terseLabel": "Lessor, Operating Lease, Term of Contract"
}
}
},
"localname": "LessorOperatingLeaseTermOfContract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LeasesDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_Liabilities": {
"auth_ref": [
"r56",
"r104",
"r182",
"r204",
"r270",
"r271",
"r272",
"r275",
"r276",
"r277",
"r279",
"r281",
"r283",
"r284",
"r442",
"r444",
"r445",
"r457",
"r500",
"r501"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
"label": "Liabilities",
"totalLabel": "Total liabilities"
}
}
},
"localname": "Liabilities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquity": {
"auth_ref": [
"r40",
"r104",
"r204",
"r457",
"r502",
"r523",
"r541"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
"label": "Liabilities and Equity",
"totalLabel": "Total liabilities and shareholders' equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities and Equity [Abstract]",
"terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY"
}
}
},
"localname": "LiabilitiesAndStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesCurrent": {
"auth_ref": [
"r13",
"r58",
"r104",
"r204",
"r270",
"r271",
"r272",
"r275",
"r276",
"r277",
"r279",
"r281",
"r283",
"r284",
"r442",
"r444",
"r445",
"r457",
"r500",
"r501",
"r502"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
"label": "Liabilities, Current",
"totalLabel": "Total current liabilities"
}
}
},
"localname": "LiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities, Current [Abstract]",
"terseLabel": "Current liabilities:"
}
}
},
"localname": "LiabilitiesCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesNoncurrent": {
"auth_ref": [
"r15",
"r16",
"r17",
"r27",
"r28",
"r104",
"r204",
"r270",
"r271",
"r272",
"r275",
"r276",
"r277",
"r279",
"r281",
"r283",
"r284",
"r442",
"r444",
"r445",
"r457",
"r500",
"r501"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
"label": "Liabilities, Noncurrent",
"totalLabel": "Total long-term liabilities"
}
}
},
"localname": "LiabilitiesNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
"auth_ref": [
"r3",
"r4",
"r6",
"r7",
"r8",
"r247",
"r251"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 10.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
"label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
"terseLabel": "Liabilities of discontinued operations"
}
}
},
"localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LicensingAgreementsMember": {
"auth_ref": [
"r437"
],
"lang": {
"en-us": {
"role": {
"documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
"label": "Licensing Agreements [Member]",
"terseLabel": "Licensing Agreements [Member]"
}
}
},
"localname": "LicensingAgreementsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsDetails",
"http://www.escalonmed.com/role/IntangibleassetsTables"
],
"xbrltype": "domainItemType"
},
"us-gaap_LineOfCreditFacilityAxis": {
"auth_ref": [
"r54",
"r103"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
"label": "Lender Name [Axis]",
"terseLabel": "Lender Name [Axis]"
}
}
},
"localname": "LineOfCreditFacilityAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditDetails",
"http://www.escalonmed.com/role/LongtermDebtTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_LineOfCreditFacilityCollateralFeesAmount": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of the fees associated with providing collateral for the credit facility.",
"label": "Line of Credit Facility, Collateral Fees, Amount",
"terseLabel": "Line of Credit Facility, Collateral Fees, Amount"
}
}
},
"localname": "LineOfCreditFacilityCollateralFeesAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": {
"auth_ref": [
"r453"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value of the amount outstanding under the credit facility.",
"label": "Line of Credit Facility, Fair Value of Amount Outstanding",
"terseLabel": "Line of Credit Facility, Fair Value of Amount Outstanding"
}
}
},
"localname": "LineOfCreditFacilityFairValueOfAmountOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
"auth_ref": [
"r54"
],
"lang": {
"en-us": {
"role": {
"documentation": "The effective interest rate at the end of the reporting period.",
"label": "Line of Credit Facility, Interest Rate at Period End",
"terseLabel": "Line of Credit Facility, Interest Rate at Period End"
}
}
},
"localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_LineOfCreditFacilityLenderDomain": {
"auth_ref": [
"r54",
"r103"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
"label": "Line of Credit Facility, Lender [Domain]",
"terseLabel": "Line of Credit Facility, Lender [Domain]"
}
}
},
"localname": "LineOfCreditFacilityLenderDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditDetails",
"http://www.escalonmed.com/role/LongtermDebtTables"
],
"xbrltype": "domainItemType"
},
"us-gaap_LineOfCreditFacilityLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Line of Credit Facility [Line Items]",
"terseLabel": "Line of Credit Facility [Line Items]"
}
}
},
"localname": "LineOfCreditFacilityLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditDetails",
"http://www.escalonmed.com/role/LongtermDebtTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_LineOfCreditFacilityPeriodicPaymentInterest": {
"auth_ref": [
"r54"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of the required periodic payment applied to interest.",
"label": "Line of Credit Facility, Periodic Payment, Interest",
"terseLabel": "Line of Credit Facility, Periodic Payment, Interest"
}
}
},
"localname": "LineOfCreditFacilityPeriodicPaymentInterest",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LineOfCreditFacilityTable": {
"auth_ref": [
"r54",
"r103"
],
"lang": {
"en-us": {
"role": {
"documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
"label": "Line of Credit Facility [Table]",
"terseLabel": "Line of Credit Facility [Table]"
}
}
},
"localname": "LineOfCreditFacilityTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditDetails",
"http://www.escalonmed.com/role/LongtermDebtTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_LineOfCreditMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
"label": "Line of Credit [Member]",
"terseLabel": "Line of Credit [Member]"
}
}
},
"localname": "LineOfCreditMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_LongTermDebt": {
"auth_ref": [
"r27",
"r299",
"r313",
"r314",
"r315",
"r522",
"r538"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
"label": "Long-Term Debt",
"terseLabel": "Long-term Debt"
}
}
},
"localname": "LongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Long-Term Debt, Unclassified [Abstract]",
"terseLabel": "Long-term Debt, Unclassified [Abstract]"
}
}
},
"localname": "LongTermDebtAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentTerms": {
"auth_ref": [
"r268",
"r336"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of timing of required repayments, sinking fund requirements, and other redeemable securities at fixed or determinable prices and dates in the five years immediately following the date of the latest balance sheet presented in the financial statements, and the amount thereafter to fully repay the principal of long-term debt. These disclosures may be made either on an individual debt or security basis, by type of debt or security basis, or on a combined basis.",
"label": "Long-Term Debt, Maturities, Repayment Terms",
"terseLabel": "Long-term Debt, Maturities, Repayment Terms"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentTerms",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
"auth_ref": [
"r109",
"r268",
"r304"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, after Year Five",
"terseLabel": "Long-Term Debt, Maturity, after Year Five"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
"auth_ref": [
"r109",
"r268",
"r304"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, Year One",
"terseLabel": "Long-Term Debt, Maturity, Year One"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
"auth_ref": [
"r109",
"r268",
"r304"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, Year Five",
"terseLabel": "Long-Term Debt, Maturity, Year Five"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
"auth_ref": [
"r109",
"r268",
"r304"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, Year Four",
"terseLabel": "Long-Term Debt, Maturity, Year Four"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
"auth_ref": [
"r109",
"r268",
"r304"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, Year Three",
"terseLabel": "Long-Term Debt, Maturity, Year Three"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
"auth_ref": [
"r109",
"r268",
"r304"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, Year Two",
"terseLabel": "Long-Term Debt, Maturity, Year Two"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
"auth_ref": [
"r59"
],
"lang": {
"en-us": {
"role": {
"documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.",
"label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
"terseLabel": "Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate"
}
}
},
"localname": "LongTermDebtPercentageBearingFixedInterestRate",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_LongTermDebtTextBlock": {
"auth_ref": [
"r318"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for long-term debt.",
"label": "Long-Term Debt [Text Block]",
"terseLabel": "Long-term Debt [Text Block]"
}
}
},
"localname": "LongTermDebtTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtNotes"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LongTermNotesPayable": {
"auth_ref": [
"r60"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesNoncurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
"label": "Notes Payable, Noncurrent",
"terseLabel": "Notes Payable, Noncurrent"
}
}
},
"localname": "LongTermNotesPayable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongtermDebtTypeAxis": {
"auth_ref": [
"r60"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of long-term debt.",
"label": "Long-Term Debt, Type [Axis]",
"terseLabel": "Long-term Debt, Type [Axis]"
}
}
},
"localname": "LongtermDebtTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows",
"http://www.escalonmed.com/role/LineofcreditDetails",
"http://www.escalonmed.com/role/LongtermDebtDetails",
"http://www.escalonmed.com/role/LongtermDebtEIDLmaturitiesTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_LongtermDebtTypeDomain": {
"auth_ref": [
"r60",
"r269"
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
"label": "Long-Term Debt, Type [Domain]",
"terseLabel": "Long-term Debt, Type [Domain]"
}
}
},
"localname": "LongtermDebtTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows",
"http://www.escalonmed.com/role/LineofcreditDetails",
"http://www.escalonmed.com/role/LongtermDebtDetails",
"http://www.escalonmed.com/role/LongtermDebtEIDLmaturitiesTables"
],
"xbrltype": "domainItemType"
},
"us-gaap_MachineryAndEquipmentGross": {
"auth_ref": [
"r248"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
"label": "Machinery and Equipment, Gross",
"terseLabel": "Equipment"
}
}
},
"localname": "MachineryAndEquipmentGross",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NatureOfOperations": {
"auth_ref": [
"r150",
"r165"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
"label": "Nature of Operations [Text Block]",
"terseLabel": "Organization and Description of Business and Business Conditions"
}
}
},
"localname": "NatureOfOperations",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/OrganizationandDescriptionofBusiness"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"auth_ref": [
"r83"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": 1.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
"label": "Net Cash Provided by (Used in) Financing Activities",
"totalLabel": "Net cash used in financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
"terseLabel": "Net Cash provided by (used in) Financing Activities:"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"auth_ref": [
"r83"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": 3.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
"label": "Net Cash Provided by (Used in) Investing Activities",
"totalLabel": "Net cash used in investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
"terseLabel": "Cash Flows from Investing Activities:"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"auth_ref": [
"r83",
"r87",
"r90"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": 2.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
"label": "Net Cash Provided by (Used in) Operating Activities",
"totalLabel": "Net cash (used in) provided by operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivities",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Cash Flows from Operating Activities:"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetIncomeLoss": {
"auth_ref": [
"r8",
"r63",
"r64",
"r68",
"r71",
"r90",
"r104",
"r115",
"r117",
"r118",
"r120",
"r121",
"r125",
"r126",
"r138",
"r176",
"r180",
"r183",
"r186",
"r188",
"r204",
"r270",
"r271",
"r272",
"r275",
"r276",
"r277",
"r279",
"r281",
"r283",
"r284",
"r450",
"r457",
"r525",
"r544"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": 9.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
},
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": {
"order": 2.0,
"parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
"label": "Net Income (Loss) Attributable to Parent",
"terseLabel": "Net income (loss)"
}
}
},
"localname": "NetIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails",
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows",
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations",
"http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
"auth_ref": [
"r117",
"r118",
"r120",
"r121",
"r128",
"r129",
"r139",
"r142",
"r176",
"r180",
"r183",
"r186",
"r188"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
"label": "Net Income (Loss) Available to Common Stockholders, Basic",
"totalLabel": "Net income (loss) applicable to common shareholders"
}
}
},
"localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
"auth_ref": [
"r130",
"r132",
"r133",
"r134",
"r135",
"r139",
"r142"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
"label": "Net Income (Loss) Available to Common Stockholders, Diluted",
"terseLabel": "Net Income (Loss) Available to Common Stockholders, Diluted"
}
}
},
"localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": {
"auth_ref": [
"r129",
"r142"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.",
"label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic",
"terseLabel": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic"
}
}
},
"localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
"label": "New Accounting Pronouncements, Policy [Policy Text Block]",
"terseLabel": "New Accounting Pronouncements"
}
}
},
"localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NonUsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Countries excluding the United States of America (US).",
"label": "Non-US [Member]",
"terseLabel": "International [Member]"
}
}
},
"localname": "NonUsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Noncash Investing and Financing Items [Abstract]",
"terseLabel": "Non Cash Finance Activities"
}
}
},
"localname": "NoncashInvestingAndFinancingItemsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
],
"xbrltype": "stringItemType"
},
"us-gaap_NonmonetaryTransactionsDisclosureTextBlock": {
"auth_ref": [
"r489",
"r490"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for exchanges with other entities that involve principally nonmonetary assets or liabilities or relate to a transfer of nonmonetary assets for which the entity receives no assets in return.",
"label": "Nonmonetary Transactions Disclosure [Text Block]",
"terseLabel": "Nonmonetary Transactions Disclosure [Text Block]"
}
}
},
"localname": "NonmonetaryTransactionsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactions"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NonoperatingIncomeExpense": {
"auth_ref": [
"r78"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
"label": "Nonoperating Income (Expense)",
"totalLabel": "Total other (expense) income"
}
}
},
"localname": "NonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NotesPayableToBank": {
"auth_ref": [
"r27",
"r522",
"r538"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Including the current and noncurrent portions, the carrying value as of the balance sheet date of notes payable to banks, excluding mortgage notes, initially due beyond one year or beyond the operating cycle if longer.",
"label": "Notes Payable to Bank",
"terseLabel": "Notes Payable to Bank"
}
}
},
"localname": "NotesPayableToBank",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NotesPayableToBankCurrent": {
"auth_ref": [
"r51"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.",
"label": "Notes Payable to Bank, Current",
"terseLabel": "Notes Payable to Bank, Current"
}
}
},
"localname": "NotesPayableToBankCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NotesPayableToBanksMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A written promise to pay a note to a bank.",
"label": "Notes Payable to Banks [Member]",
"terseLabel": "Notes Payable to Banks [Member]"
}
}
},
"localname": "NotesPayableToBanksMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_OperatingIncomeLoss": {
"auth_ref": [
"r176",
"r180",
"r183",
"r186",
"r188"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net result for the period of deducting operating expenses from operating revenues.",
"label": "Operating Income (Loss)",
"totalLabel": "Loss from operations"
}
}
},
"localname": "OperatingIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseExpense": {
"auth_ref": [
"r477"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of operating lease expense. Excludes sublease income.",
"label": "Operating Lease, Expense",
"terseLabel": "Operating Lease, Expense"
}
}
},
"localname": "OperatingLeaseExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LeasesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiability": {
"auth_ref": [
"r475"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
"label": "Operating Lease, Liability",
"terseLabel": "Operating Lease, Liability"
}
}
},
"localname": "OperatingLeaseLiability",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LeasesDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesLeaseDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityCurrent": {
"auth_ref": [
"r475"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 8.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
"label": "Operating Lease, Liability, Current",
"terseLabel": "Operating Lease, Liability, Current"
}
}
},
"localname": "OperatingLeaseLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"http://www.escalonmed.com/role/LeasesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityNoncurrent": {
"auth_ref": [
"r475"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesNoncurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
"label": "Operating Lease, Liability, Noncurrent",
"terseLabel": "Operating Lease, Liability, Noncurrent"
}
}
},
"localname": "OperatingLeaseLiabilityNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"http://www.escalonmed.com/role/LeasesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
"auth_ref": [
"r476"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
"label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
"terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
}
}
},
"localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "enumerationSetItemType"
},
"us-gaap_OperatingLeaseRightOfUseAsset": {
"auth_ref": [
"r474"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's right to use underlying asset under operating lease.",
"label": "Operating Lease, Right-of-Use Asset",
"terseLabel": "Operating Lease, Right-of-Use Asset"
}
}
},
"localname": "OperatingLeaseRightOfUseAsset",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"http://www.escalonmed.com/role/LeasesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
"auth_ref": [
"r483",
"r486"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average discount rate for operating lease calculated at point in time.",
"label": "Operating Lease, Weighted Average Discount Rate, Percent",
"terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent"
}
}
},
"localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LeasesDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
"auth_ref": [
"r482",
"r486"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Operating Lease, Weighted Average Remaining Lease Term",
"terseLabel": "Operating Lease, Weighted Average Remaining Lease Term"
}
}
},
"localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LeasesDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_OperatingLeasesFutureMinimumPaymentsReceivableRemainderOfFiscalYear": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of required minimum rental payments receivable in the remainder of the fiscal year following the latest fiscal year ended for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
"label": "Operating Leases, Future Minimum Payments Receivable, Remainder of Fiscal Year",
"terseLabel": "Operating Leases, Future Minimum Payments Receivable, Remainder of Fiscal Year"
}
}
},
"localname": "OperatingLeasesFutureMinimumPaymentsReceivableRemainderOfFiscalYear",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LeasesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLossCarryforwards": {
"auth_ref": [
"r417"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
"label": "Operating Loss Carryforwards",
"terseLabel": "Operating Loss Carryforwards"
}
}
},
"localname": "OperatingLossCarryforwards",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails",
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLossCarryforwardsLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Operating Loss Carryforwards [Line Items]",
"terseLabel": "Operating Loss Carryforwards [Line Items]"
}
}
},
"localname": "OperatingLossCarryforwardsLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_OperatingLossCarryforwardsTable": {
"auth_ref": [
"r418"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
"label": "Operating Loss Carryforwards [Table]",
"terseLabel": "Operating Loss Carryforwards [Table]"
}
}
},
"localname": "OperatingLossCarryforwardsTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
"terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
}
}
},
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_OtherAccruedLiabilitiesCurrent": {
"auth_ref": [
"r57"
],
"calculation": {
"http://www.escalonmed.com/role/AccruedexpenseDetails": {
"order": 4.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
"label": "Other Accrued Liabilities, Current",
"terseLabel": "Other Accrued Liabilities, Current"
}
}
},
"localname": "OtherAccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/AccruedexpenseDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherAssetsCurrent": {
"auth_ref": [
"r49",
"r502"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 5.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of current assets classified as other.",
"label": "Other Assets, Current",
"terseLabel": "Other current assets"
}
}
},
"localname": "OtherAssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherIncomeAndExpensesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Other Income and Expenses [Abstract]",
"terseLabel": "Other (expense) income:"
}
}
},
"localname": "OtherIncomeAndExpensesAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "stringItemType"
},
"us-gaap_OtherLiabilitiesNoncurrent": {
"auth_ref": [
"r61"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 5.0,
"parentTag": "us-gaap_LiabilitiesNoncurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
"label": "Other Liabilities, Noncurrent",
"terseLabel": "Other Liabilities, Noncurrent"
}
}
},
"localname": "OtherLiabilitiesNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherLongTermDebt": {
"auth_ref": [
"r27",
"r522",
"r538"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt classified as other.",
"label": "Other Long-Term Debt",
"terseLabel": "Other Long-term Debt"
}
}
},
"localname": "OtherLongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherLongTermNotesPayable": {
"auth_ref": [
"r60"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesNoncurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer.",
"label": "Other Notes Payable, Noncurrent",
"terseLabel": "Other Notes Payable, Noncurrent"
}
}
},
"localname": "OtherLongTermNotesPayable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherNoncashIncomeExpense": {
"auth_ref": [
"r90"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
"label": "Other Noncash Income (Expense)",
"negatedTerseLabel": "Other Noncash Income (Expense)"
}
}
},
"localname": "OtherNoncashIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherNonoperatingIncomeExpense": {
"auth_ref": [
"r79"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": {
"order": 1.0,
"parentTag": "us-gaap_NonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
"label": "Other Nonoperating Income (Expense)",
"terseLabel": "Other Nonoperating Income (Expense)"
}
}
},
"localname": "OtherNonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherNotesPayableCurrent": {
"auth_ref": [
"r57"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.",
"label": "Other Notes Payable, Current",
"terseLabel": "Other Notes Payable, Current"
}
}
},
"localname": "OtherNotesPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherOperatingActivitiesCashFlowStatement": {
"auth_ref": [
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": 6.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
"label": "Other Operating Activities, Cash Flow Statement",
"terseLabel": "Non cash lease expense"
}
}
},
"localname": "OtherOperatingActivitiesCashFlowStatement",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PayablesAndAccrualsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Payables and Accruals [Abstract]",
"terseLabel": "Payables and Accruals [Abstract]"
}
}
},
"localname": "PayablesAndAccrualsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_PaymentsToAcquireOtherProductiveAssets": {
"auth_ref": [
"r80"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
"label": "Payments to Acquire Other Productive Assets",
"terseLabel": "Payments to Acquire Other Productive Assets"
}
}
},
"localname": "PaymentsToAcquireOtherProductiveAssets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquireProductiveAssets": {
"auth_ref": [
"r80",
"r438",
"r439",
"r440"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
"label": "Payments to Acquire Productive Assets",
"negatedLabel": "Purchase of equipment"
}
}
},
"localname": "PaymentsToAcquireProductiveAssets",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentAndNoncurrent": {
"auth_ref": [
"r356",
"r357",
"r521",
"r536"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits.",
"label": "Liability, Retirement and Postemployment Benefits",
"periodEndLabel": "Balance July 1,",
"periodStartLabel": "Balance July 1,",
"terseLabel": "Accrued retirement benefits"
}
}
},
"localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentAndNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/RetirementandpostretirementplansDetails",
"http://www.escalonmed.com/role/RetirementandpostretirementplansliabilityrollforwardDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PensionAndOtherPostretirementBenefitContributions": {
"auth_ref": [
"r86"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow for pension and other postretirement benefits. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree.",
"label": "Payment for Pension and Other Postretirement Benefits",
"negatedTerseLabel": "Payment of benefits",
"terseLabel": "Supplemental retirement benefits, monthly payment"
}
}
},
"localname": "PensionAndOtherPostretirementBenefitContributions",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/RetirementandpostretirementplansDetails",
"http://www.escalonmed.com/role/RetirementandpostretirementplansliabilityrollforwardDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PostemploymentBenefitsDisclosureTextBlock": {
"auth_ref": [
"r354",
"r355"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for postemployment benefits, which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.",
"label": "Postemployment Benefits Disclosure [Text Block]",
"terseLabel": "Retirement and Post-Retirement Plans"
}
}
},
"localname": "PostemploymentBenefitsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/RetirementandpostretirementplansNotes"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_PreferredStockAmountOfPreferredDividendsInArrears": {
"auth_ref": [
"r337"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate amount of cumulative preferred dividends in arrears.",
"label": "Preferred Stock, Amount of Preferred Dividends in Arrears",
"terseLabel": "Dividends Payable, Date to be Paid"
}
}
},
"localname": "PreferredStockAmountOfPreferredDividendsInArrears",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PreferredStockDividendsAndOtherAdjustments": {
"auth_ref": [
"r129",
"r143"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": {
"order": 1.0,
"parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
"label": "Preferred Stock Dividends and Other Adjustments",
"terseLabel": "Undeclared dividends on preferred stocks"
}
}
},
"localname": "PreferredStockDividendsAndOtherAdjustments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PreferredStockDividendsIncomeStatementImpact": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
"label": "Preferred Stock Dividends, Income Statement Impact",
"terseLabel": "Preferred Stock Dividends, Income Statement Impact"
}
}
},
"localname": "PreferredStockDividendsIncomeStatementImpact",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PreferredStockMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
"label": "Preferred Stock [Member]",
"terseLabel": "Preferred Stock [Member]"
}
}
},
"localname": "PreferredStockMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss"
],
"xbrltype": "domainItemType"
},
"us-gaap_PreferredStockParOrStatedValuePerShare": {
"auth_ref": [
"r34",
"r319"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
"label": "Preferred Stock, Par or Stated Value Per Share",
"terseLabel": "Preferred stock, par value"
}
}
},
"localname": "PreferredStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "perShareItemType"
},
"us-gaap_PreferredStockSharesAuthorized": {
"auth_ref": [
"r34"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
"label": "Preferred Stock, Shares Authorized",
"terseLabel": "Preferred stock, shares authorized"
}
}
},
"localname": "PreferredStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesIssued": {
"auth_ref": [
"r34",
"r319"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
"label": "Preferred Stock, Shares Issued",
"terseLabel": "Preferred Stock, Shares Issued"
}
}
},
"localname": "PreferredStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesOutstanding": {
"auth_ref": [
"r34"
],
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
"label": "Preferred Stock, Shares Outstanding",
"terseLabel": "Preferred Stock, Shares Outstanding"
}
}
},
"localname": "PreferredStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockValue": {
"auth_ref": [
"r34",
"r502"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Preferred Stock, Value, Issued",
"terseLabel": "Preferred Stock, Value, Issued",
"verboseLabel": "Series A convertible preferred stock, $0.001 par value; 2,000,000 shares authorized;2,000,000 issued and outstanding"
}
}
},
"localname": "PreferredStockValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PrimeRateMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
"label": "Prime Rate [Member]",
"terseLabel": "Prime Rate [Member]"
}
}
},
"localname": "PrimeRateMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
"auth_ref": [
"r2"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
"label": "Reclassification, Comparability Adjustment [Policy Text Block]",
"terseLabel": "Reclassification, Comparability Adjustment [Policy Text Block]"
}
}
},
"localname": "PriorPeriodReclassificationAdjustmentDescription",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ProductMember": {
"auth_ref": [
"r349"
],
"lang": {
"en-us": {
"role": {
"documentation": "Article or substance produced by nature, labor or machinery.",
"label": "Product [Member]",
"terseLabel": "Product [Member]"
}
}
},
"localname": "ProductMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "domainItemType"
},
"us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
"auth_ref": [
"r57",
"r265",
"r266"
],
"calculation": {
"http://www.escalonmed.com/role/AccruedexpenseDetails": {
"order": 2.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Product Warranty Accrual, Current",
"terseLabel": "Product Warranty Accrual, Current"
}
}
},
"localname": "ProductWarrantyAccrualClassifiedCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/AccruedexpenseDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Property, Plant and Equipment [Abstract]",
"terseLabel": "Property, Plant and Equipment [Abstract]"
}
}
},
"localname": "PropertyPlantAndEquipmentAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
"auth_ref": [
"r250"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
"label": "Long-Lived Tangible Asset [Axis]",
"terseLabel": "Long-Lived Tangible Asset [Axis]"
}
}
},
"localname": "PropertyPlantAndEquipmentByTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentTables",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_PropertyPlantAndEquipmentGross": {
"auth_ref": [
"r19",
"r248"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
"label": "Property, Plant and Equipment, Gross",
"terseLabel": "Property, Plant and Equipment, Gross"
}
}
},
"localname": "PropertyPlantAndEquipmentGross",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Property, Plant and Equipment [Line Items]",
"terseLabel": "Property, Plant and Equipment [Line Items]"
}
}
},
"localname": "PropertyPlantAndEquipmentLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentTables",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_PropertyPlantAndEquipmentNet": {
"auth_ref": [
"r250",
"r502",
"r529",
"r542"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
"label": "Property, Plant and Equipment, Net",
"netLabel": "Property, Plant and Equipment, Net"
}
}
},
"localname": "PropertyPlantAndEquipmentNet",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
"auth_ref": [
"r250",
"r566",
"r567"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
"label": "Property, Plant and Equipment, Policy [Policy Text Block]",
"terseLabel": "Property, Plant and Equipment, Policy [Policy Text Block]"
}
}
},
"localname": "PropertyPlantAndEquipmentPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_PropertyPlantAndEquipmentTextBlock": {
"auth_ref": [
"r250"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
"label": "Property, Plant and Equipment [Table Text Block]",
"terseLabel": "Property, Plant and Equipment [Table Text Block]"
}
}
},
"localname": "PropertyPlantAndEquipmentTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_PropertyPlantAndEquipmentTypeDomain": {
"auth_ref": [
"r248"
],
"lang": {
"en-us": {
"role": {
"documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
"label": "Long-Lived Tangible Asset [Domain]",
"terseLabel": "Long-Lived Tangible Asset [Domain]"
}
}
},
"localname": "PropertyPlantAndEquipmentTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentTables",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_PropertyPlantAndEquipmentUsefulLife": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
"label": "Property, Plant and Equipment, Useful Life",
"terseLabel": "Property, Plant and Equipment, Useful Life"
}
}
},
"localname": "PropertyPlantAndEquipmentUsefulLife",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_ProvisionForDoubtfulAccounts": {
"auth_ref": [
"r73",
"r210"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": 7.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
"label": "Accounts Receivable, Credit Loss Expense (Reversal)",
"terseLabel": "Increase in accounts receivable allowance"
}
}
},
"localname": "ProvisionForDoubtfulAccounts",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RelatedPartyTransactionDueFromToRelatedParty": {
"auth_ref": [
"r108",
"r273",
"r275",
"r276",
"r282",
"r283",
"r284",
"r495"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.",
"label": "Related Party Transaction, Due from (to) Related Party",
"terseLabel": "Related Party Transaction, Due from (to) Related Party"
}
}
},
"localname": "RelatedPartyTransactionDueFromToRelatedParty",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RelatedPartyTransactionLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Related Party Transaction [Line Items]",
"terseLabel": "Related Party Transaction [Line Items]"
}
}
},
"localname": "RelatedPartyTransactionLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RelatedPartyTransactionsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Related Party Transactions [Abstract]",
"terseLabel": "Related Party Transactions [Abstract]"
}
}
},
"localname": "RelatedPartyTransactionsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
"auth_ref": [
"r493",
"r494",
"r495",
"r498",
"r499"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
"label": "Related Party Transactions Disclosure [Text Block]",
"terseLabel": "Related Party Transactions"
}
}
},
"localname": "RelatedPartyTransactionsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/RelatedPartyTransactions"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RepaymentsOfNotesPayable": {
"auth_ref": [
"r81"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
"label": "Repayments of Notes Payable",
"negatedTerseLabel": "Repayment of note payable"
}
}
},
"localname": "RepaymentsOfNotesPayable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RepaymentsOfSecuredDebt": {
"auth_ref": [
"r81"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
"label": "Repayments of Secured Debt",
"terseLabel": "Repayments of Secured Debt"
}
}
},
"localname": "RepaymentsOfSecuredDebt",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpense": {
"auth_ref": [
"r403",
"r512",
"r580"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": {
"order": 2.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
"label": "Research and Development Expense",
"terseLabel": "Research and development"
}
}
},
"localname": "ResearchAndDevelopmentExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpensePolicy": {
"auth_ref": [
"r403"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
"label": "Research and Development Expense, Policy [Policy Text Block]",
"terseLabel": "Research and Development Expense, Policy [Policy Text Block]"
}
}
},
"localname": "ResearchAndDevelopmentExpensePolicy",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
"auth_ref": [
"r245",
"r246",
"r580"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.",
"label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
"terseLabel": "Research, Development, and Computer Software, Policy [Policy Text Block]"
}
}
},
"localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RestrictedCash": {
"auth_ref": [
"r18",
"r95",
"r516",
"r539"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlowsParenthetical": {
"order": 2.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
"label": "Restricted Cash",
"terseLabel": "Restricted Cash",
"verboseLabel": "Restricted Cash"
}
}
},
"localname": "RestrictedCash",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestrictedCashCurrent": {
"auth_ref": [
"r18",
"r95"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
"label": "Restricted Cash, Current",
"terseLabel": "Restricted Cash, Current"
}
}
},
"localname": "RestrictedCashCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsAccumulatedDeficit": {
"auth_ref": [
"r37",
"r342",
"r502",
"r540",
"r556",
"r561"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings (Accumulated Deficit)",
"terseLabel": "Accumulated deficit",
"verboseLabel": "Retained Earnings (Accumulated Deficit)"
}
}
},
"localname": "RetainedEarningsAccumulatedDeficit",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"http://www.escalonmed.com/role/GoingconcernDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsMember": {
"auth_ref": [
"r0",
"r112",
"r113",
"r114",
"r116",
"r123",
"r126",
"r205",
"r399",
"r400",
"r401",
"r424",
"r425",
"r448",
"r552",
"r554"
],
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings [Member]",
"terseLabel": "Accumulated Deficit [Member]"
}
}
},
"localname": "RetainedEarningsMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails",
"http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss"
],
"xbrltype": "domainItemType"
},
"us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
"auth_ref": [
"r167",
"r168",
"r179",
"r184",
"r185",
"r189",
"r190",
"r192",
"r346",
"r347",
"r513"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": {
"order": 1.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
"label": "Revenue from Contract with Customer, Including Assessed Tax",
"terseLabel": "Revenue from Contract with Customer, Including Assessed Tax"
}
}
},
"localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Revenue Recognition and Deferred Revenue [Abstract]",
"terseLabel": "Revenue Recognition and Deferred Revenue [Abstract]"
}
}
},
"localname": "RevenueRecognitionAndDeferredRevenueAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_RevenueRecognitionPolicyTextBlock": {
"auth_ref": [
"r99",
"r100"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
"label": "Revenue [Policy Text Block]",
"terseLabel": "Revenue Recognition"
}
}
},
"localname": "RevenueRecognitionPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_Revenues": {
"auth_ref": [
"r70",
"r104",
"r167",
"r168",
"r179",
"r184",
"r185",
"r189",
"r190",
"r192",
"r204",
"r270",
"r271",
"r272",
"r275",
"r276",
"r277",
"r279",
"r281",
"r283",
"r284",
"r457",
"r528"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
"label": "Revenues",
"terseLabel": "Revenues"
}
}
},
"localname": "Revenues",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SalesAndExciseTaxPayableCurrentAndNoncurrent": {
"auth_ref": [
"r524",
"r543"
],
"calculation": {
"http://www.escalonmed.com/role/AccruedexpenseDetails": {
"order": 1.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax.",
"label": "Sales and Excise Tax Payable",
"terseLabel": "Sales and Excise Tax Payable"
}
}
},
"localname": "SalesAndExciseTaxPayableCurrentAndNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/AccruedexpenseDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SalesRevenueNetMember": {
"auth_ref": [
"r158",
"r192"
],
"lang": {
"en-us": {
"role": {
"documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
"label": "Revenue Benchmark [Member]",
"terseLabel": "Revenue Benchmark"
}
}
},
"localname": "SalesRevenueNetMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the components of accrued liabilities.",
"label": "Schedule of Accrued Liabilities [Table Text Block]",
"terseLabel": "Schedule of Accrued Liabilities [Table Text Block]"
}
}
},
"localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/AccruedexpenseNotes",
"http://www.escalonmed.com/role/AccruedexpenseTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
"auth_ref": [
"r144"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
"label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
"terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
}
}
},
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
"auth_ref": [
"r144"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
"label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
"terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]"
}
}
},
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
"auth_ref": [
"r423"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
"label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
"terseLabel": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]"
}
}
},
"localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTextBlock": {
"auth_ref": [
"r352",
"r353"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of arrangements with individual employees that are not equity-based payments or pensions and other postretirement benefits, which are generally employment contracts between the entity and selected officers or key employees containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Examples may include profit sharing, deferred bonuses or certain split-dollar life insurance arrangements. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
"label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits by Title of Individual and Type of Deferred Compensation [Table Text Block]",
"terseLabel": "Rollforward of Supplemental Retirement Benefits"
}
}
},
"localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/RetirementandpostretirementplansTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
"auth_ref": [
"r414"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
"label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
"terseLabel": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]"
}
}
},
"localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
"auth_ref": [
"r142"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
"label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
"terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]"
}
}
},
"localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
"auth_ref": [
"r406"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
"label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
"terseLabel": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]"
}
}
},
"localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
"auth_ref": [
"r189"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
"label": "Revenue from External Customers by Products and Services [Table]",
"terseLabel": "Revenue from External Customers by Products and Services [Table]"
}
}
},
"localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
"auth_ref": [
"r234",
"r237",
"r514"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
"label": "Schedule of Finite-Lived Intangible Assets [Table]",
"terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
}
}
},
"localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
"auth_ref": [
"r234",
"r237"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
"label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
"terseLabel": "Schedule of Finite-Lived Intangible Assets [Table Text Block]"
}
}
},
"localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
"auth_ref": [
"r240",
"r243"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
"label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
"terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]"
}
}
},
"localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
"auth_ref": [
"r230"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
"label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
"terseLabel": "Schedule of Intangible Assets and Goodwill [Table Text Block]"
}
}
},
"localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
"auth_ref": [
"r14",
"r45",
"r46",
"r47"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
"label": "Schedule of Inventory, Current [Table Text Block]",
"terseLabel": "Schedule of Inventory, Current [Table Text Block]"
}
}
},
"localname": "ScheduleOfInventoryCurrentTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
"auth_ref": [
"r268"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
"label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
"terseLabel": "Schedule of Maturities of Long-term Debt [Table Text Block]"
}
}
},
"localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtEIDLmaturitiesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
"auth_ref": [
"r250"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
"label": "Property, Plant and Equipment [Table]",
"terseLabel": "Property, Plant and Equipment [Table]"
}
}
},
"localname": "ScheduleOfPropertyPlantAndEquipmentTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertyPlantandEquipmentTables",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPropertypantandequipmentDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
"auth_ref": [
"r496",
"r497"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
"label": "Schedule of Related Party Transactions, by Related Party [Table]",
"terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
}
}
},
"localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/RelatedPartyTransactionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
"auth_ref": [
"r95",
"r516",
"r539"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
"label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
"terseLabel": "Restrictions on Cash and Cash Equivalents [Table Text Block]"
}
}
},
"localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
"auth_ref": [
"r363",
"r364",
"r365",
"r366",
"r367",
"r369",
"r370",
"r371",
"r372",
"r373",
"r374",
"r375",
"r376",
"r377",
"r378",
"r379",
"r380",
"r381",
"r382",
"r385",
"r386",
"r388",
"r389",
"r391",
"r392",
"r393",
"r394",
"r395"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about share-based payment arrangement.",
"label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
"terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
}
}
},
"localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails",
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
"auth_ref": [
"r397"
],
"lang": {
"en-us": {
"role": {
"documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
"label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
"terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]"
}
}
},
"localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesStockBasedCompensationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
"auth_ref": [
"r397"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
"label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
"terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]"
}
}
},
"localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
"auth_ref": [
"r368",
"r384",
"r387"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
"label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
"terseLabel": "Share-based Payment Arrangement, Option, Activity [Table Text Block]"
}
}
},
"localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable": {
"auth_ref": [
"r397",
"r398"
],
"lang": {
"en-us": {
"role": {
"documentation": "Details pertaining to each transaction in which an entity acquires goods or services other than employee services in exchange for equity securities of the company, including the purpose of the transaction, identification and quantity of the securities issued, the accounting made, disclosure of amounts by which report lines were affected, and noncash effects on the statement of cash flows.",
"label": "Schedule of Share-Based Goods and Nonemployee Services Transaction [Table]",
"terseLabel": "Schedule of Share-based Goods and Nonemployee Services Transaction [Table]"
}
}
},
"localname": "ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsCompensationrelatedcostDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
"auth_ref": [
"r155",
"r158",
"r159",
"r160",
"r454",
"r456"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
"label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
"terseLabel": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]"
}
}
},
"localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SecuredDebtCurrent": {
"auth_ref": [
"r25",
"r518",
"r537"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.",
"label": "Secured Debt, Current",
"terseLabel": "Secured Debt, Current"
}
}
},
"localname": "SecuredDebtCurrent",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SecuredDebtMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
"label": "Secured Debt [Member]",
"terseLabel": "Secured Debt [Member]"
}
}
},
"localname": "SecuredDebtMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"http://www.escalonmed.com/role/LongtermDebtDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_SecuredLongTermDebt": {
"auth_ref": [
"r60"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_LiabilitiesNoncurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.",
"label": "Secured Long-Term Debt, Noncurrent",
"terseLabel": "Long-term Debt"
}
}
},
"localname": "SecuredLongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SegmentDomain": {
"auth_ref": [
"r166",
"r167",
"r168",
"r169",
"r170",
"r171",
"r172",
"r173",
"r174",
"r175",
"r176",
"r177",
"r178",
"r179",
"r180",
"r181",
"r182",
"r183",
"r184",
"r185",
"r186",
"r187",
"r188",
"r192",
"r222",
"r223",
"r224",
"r225",
"r226",
"r227",
"r228",
"r229",
"r230",
"r232",
"r254",
"r255",
"r546"
],
"lang": {
"en-us": {
"role": {
"documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
"label": "Segments [Domain]",
"terseLabel": "Segments [Domain]"
}
}
},
"localname": "SegmentDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsTables"
],
"xbrltype": "domainItemType"
},
"us-gaap_SellingGeneralAndAdministrativeExpense": {
"auth_ref": [
"r76"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations": {
"order": 1.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
"label": "Selling, General and Administrative Expense",
"terseLabel": "Marketing, general and administrative"
}
}
},
"localname": "SellingGeneralAndAdministrativeExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ServiceMember": {
"auth_ref": [
"r349"
],
"lang": {
"en-us": {
"role": {
"documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
"label": "Service [Member]",
"terseLabel": "Service [Member]"
}
}
},
"localname": "ServiceMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
"auth_ref": [
"r365"
],
"lang": {
"en-us": {
"role": {
"documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
"verboseLabel": "Vesting period"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails",
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesStockBasedCompensationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
"auth_ref": [
"r397"
],
"lang": {
"en-us": {
"role": {
"documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
"auth_ref": [
"r371"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails",
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
"auth_ref": [
"r371"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails",
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
"auth_ref": [
"r375"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
"negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
"auth_ref": [
"r373"
],
"lang": {
"en-us": {
"role": {
"documentation": "Gross number of share options (or share units) granted during the period.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r385"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
"auth_ref": [
"r369",
"r370"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of options outstanding, including both vested and non-vested options.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails",
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
"terseLabel": "Common Stock Options [Roll Forward]"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
"auth_ref": [
"r369",
"r370"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails",
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
"terseLabel": "Weighted Average Exercise Price [Roll Forward]"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
"auth_ref": [
"r365",
"r366",
"r367",
"r369",
"r370",
"r371",
"r372",
"r373",
"r374",
"r375",
"r376",
"r377",
"r378",
"r379",
"r380",
"r381",
"r382",
"r385",
"r386",
"r388",
"r389",
"r391",
"r392",
"r393",
"r394",
"r395"
],
"lang": {
"en-us": {
"role": {
"documentation": "Award under share-based payment arrangement.",
"label": "Award Type [Domain]",
"terseLabel": "Award Type [Domain]",
"verboseLabel": "Award Type [Domain]"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsCompensationrelatedcostDetails",
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesStockBasedCompensationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r374"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
"label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
"terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r375"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
"label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
"terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
"auth_ref": [
"r373"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
"label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
"terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
"auth_ref": [
"r390"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by range of option prices pertaining to options granted.",
"label": "Exercise Price Range [Axis]",
"terseLabel": "Exercise Price Range [Axis]"
}
}
},
"localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails",
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
"auth_ref": [
"r396"
],
"lang": {
"en-us": {
"role": {
"documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
"label": "Exercise Price Range [Domain]",
"terseLabel": "Exercise Price Range [Domain]"
}
}
},
"localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails",
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
"auth_ref": [
"r383"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
"label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
"terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable"
}
}
},
"localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails",
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by supplier.",
"label": "Supplier [Axis]",
"terseLabel": "Supplier [Axis]"
}
}
},
"localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsCompensationrelatedcostDetails",
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Share-Based Goods and Nonemployee Services Transaction [Line Items]",
"terseLabel": "Share-based Goods and Nonemployee Services Transaction [Line Items]"
}
}
},
"localname": "ShareBasedGoodsAndNonemployeeServicesTransactionLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsCompensationrelatedcostDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received.",
"label": "Supplier [Domain]",
"terseLabel": "Supplier [Domain]"
}
}
},
"localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsCompensationrelatedcostDetails",
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
"auth_ref": [
"r388"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term"
}
}
},
"localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails",
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionPlansNarrativeDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_SharesOutstanding": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
"label": "Shares, Outstanding",
"periodEndLabel": "Balance, shares",
"periodStartLabel": "Balance, shares"
}
}
},
"localname": "SharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShippingAndHandlingCostPolicyTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.",
"label": "Shipping and Handling Cost, Policy [Policy Text Block]",
"terseLabel": "Shipping and Handling Cost, Policy [Policy Text Block]"
}
}
},
"localname": "ShippingAndHandlingCostPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ShortTermBorrowings": {
"auth_ref": [
"r24",
"r502",
"r518",
"r537"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
"label": "Short-Term Debt",
"terseLabel": "Short-term Debt"
}
}
},
"localname": "ShortTermBorrowings",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShortTermDebtTypeAxis": {
"auth_ref": [
"r55"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of short-term debt arrangement.",
"label": "Short-Term Debt, Type [Axis]",
"terseLabel": "Short-term Debt, Type [Axis]"
}
}
},
"localname": "ShortTermDebtTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShortTermDebtTypeDomain": {
"auth_ref": [
"r52"
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
"label": "Short-Term Debt, Type [Domain]",
"terseLabel": "Short-term Debt, Type [Domain]"
}
}
},
"localname": "ShortTermDebtTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShortTermLeasePayments": {
"auth_ref": [
"r478"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow for short-term lease payment excluded from lease liability.",
"label": "Short-Term Lease Payments",
"terseLabel": "Short-term Lease Payments"
}
}
},
"localname": "ShortTermLeasePayments",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LeasesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SignificantAccountingPoliciesTextBlock": {
"auth_ref": [
"r96",
"r111"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
"label": "Significant Accounting Policies [Text Block]",
"terseLabel": "Significant Accounting Policies"
}
}
},
"localname": "SignificantAccountingPoliciesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_StandardProductWarrantyPolicy": {
"auth_ref": [
"r267"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.",
"label": "Standard Product Warranty, Policy [Policy Text Block]",
"terseLabel": "Accrued Warranties"
}
}
},
"localname": "StandardProductWarrantyPolicy",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_StateAndLocalJurisdictionMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
"label": "State and Local Jurisdiction [Member]",
"terseLabel": "State and Local Jurisdiction [Member]"
}
}
},
"localname": "StateAndLocalJurisdictionMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_StatementBusinessSegmentsAxis": {
"auth_ref": [
"r5",
"r166",
"r167",
"r168",
"r169",
"r170",
"r171",
"r172",
"r173",
"r174",
"r175",
"r176",
"r177",
"r178",
"r179",
"r180",
"r181",
"r182",
"r183",
"r184",
"r185",
"r186",
"r187",
"r188",
"r192",
"r222",
"r223",
"r224",
"r225",
"r226",
"r227",
"r228",
"r229",
"r230",
"r232",
"r252",
"r254",
"r255",
"r546"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by business segments.",
"label": "Segments [Axis]",
"terseLabel": "Segments [Axis]"
}
}
},
"localname": "StatementBusinessSegmentsAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementEquityComponentsAxis": {
"auth_ref": [
"r0",
"r62",
"r66",
"r67",
"r68",
"r112",
"r113",
"r114",
"r116",
"r123",
"r126",
"r149",
"r205",
"r335",
"r342",
"r399",
"r400",
"r401",
"r424",
"r425",
"r448",
"r459",
"r460",
"r461",
"r462",
"r463",
"r464",
"r492",
"r552",
"r553",
"r554"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by component of equity.",
"label": "Equity Components [Axis]",
"terseLabel": "Statement, Equity Components [Axis]",
"verboseLabel": "Equity Components [Axis]"
}
}
},
"localname": "StatementEquityComponentsAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactionsStockOptionActivityDetails",
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails",
"http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Statement [Line Items]",
"terseLabel": "Statement [Line Items]"
}
}
},
"localname": "StatementLineItems",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows",
"http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss",
"http://www.escalonmed.com/role/IntangibleassetsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfCashFlowsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement of Cash Flows [Abstract]",
"terseLabel": "Statement of Cash Flows [Abstract]"
}
}
},
"localname": "StatementOfCashFlowsAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfFinancialPositionAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement of Financial Position [Abstract]",
"terseLabel": "Statement of Financial Position [Abstract]"
}
}
},
"localname": "StatementOfFinancialPositionAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfStockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement of Stockholders' Equity [Abstract]",
"terseLabel": "Statement of Stockholders' Equity [Abstract]"
}
}
},
"localname": "StatementOfStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StatementTable": {
"auth_ref": [
"r112",
"r113",
"r114",
"r149",
"r513"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
"label": "Statement [Table]",
"terseLabel": "Statement [Table]"
}
}
},
"localname": "StatementTable",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlows",
"http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss",
"http://www.escalonmed.com/role/IntangibleassetsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockOptionMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
"label": "Equity Option [Member]",
"terseLabel": "Equity Option [Member]"
}
}
},
"localname": "StockOptionMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_StockholdersEquity": {
"auth_ref": [
"r35",
"r38",
"r39",
"r104",
"r201",
"r204",
"r457",
"r502"
],
"calculation": {
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
"label": "Stockholders' Equity Attributable to Parent",
"periodEndLabel": "Balance",
"periodStartLabel": "Balance",
"totalLabel": "Total shareholders' equity"
}
}
},
"localname": "StockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets",
"http://www.escalonmed.com/role/ConsolidatedStatementsOfShareholdersEquityandComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Stockholders' Equity Attributable to Parent [Abstract]",
"terseLabel": "Shareholders equity:"
}
}
},
"localname": "StockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockholdersEquityNoteAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Stockholders' Equity Note [Abstract]",
"terseLabel": "Stockholders' Equity Note [Abstract]"
}
}
},
"localname": "StockholdersEquityNoteAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"xbrltype": "stringItemType"
},
"us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
"auth_ref": [
"r102",
"r320",
"r322",
"r323",
"r324",
"r325",
"r326",
"r327",
"r328",
"r330",
"r332",
"r333",
"r334",
"r342",
"r343",
"r446"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
"label": "Stockholders' Equity Note Disclosure [Text Block]",
"terseLabel": "Stockholders' Equity Note Disclosure [Text Block]"
}
}
},
"localname": "StockholdersEquityNoteDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/CapitalStockTransactions"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
"auth_ref": [
"r9"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
"label": "Substantial Doubt about Going Concern [Text Block]",
"terseLabel": "Liquidity Disclosure [Policy Text Block]"
}
}
},
"localname": "SubstantialDoubtAboutGoingConcernTextBlock",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/GoingconcernNotes"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SupplementalCashFlowInformationAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Supplemental Cash Flow Information [Abstract]",
"terseLabel": "Supplemental Schedule of Cash Flow Information:"
}
}
},
"localname": "SupplementalCashFlowInformationAbstract",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
],
"xbrltype": "stringItemType"
},
"us-gaap_SupplierConcentrationRiskMember": {
"auth_ref": [
"r156"
],
"lang": {
"en-us": {
"role": {
"documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
"label": "Supplier Concentration Risk [Member]",
"terseLabel": "Supplier Concentration Risk [Member]"
}
}
},
"localname": "SupplierConcentrationRiskMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConcentrationofcreditriskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_TaxCreditCarryforwardValuationAllowance": {
"auth_ref": [
"r413"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.",
"label": "Tax Credit Carryforward, Valuation Allowance",
"terseLabel": "Tax Credit Carryforward, Valuation Allowance"
}
}
},
"localname": "TaxCreditCarryforwardValuationAllowance",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_TradeAndOtherAccountsReceivablePolicy": {
"auth_ref": [
"r195",
"r196",
"r197",
"r198",
"r200",
"r202"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for accounts receivable.",
"label": "Accounts Receivable [Policy Text Block]",
"terseLabel": "Accounts Receivable"
}
}
},
"localname": "TradeAndOtherAccountsReceivablePolicy",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_TrademarksAndTradeNamesMember": {
"auth_ref": [
"r436"
],
"lang": {
"en-us": {
"role": {
"documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
"label": "Trademarks and Trade Names [Member]",
"terseLabel": "Trademarks and Trade Names [Member]"
}
}
},
"localname": "TrademarksAndTradeNamesMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IntangibleassetsTables"
],
"xbrltype": "domainItemType"
},
"us-gaap_UnsecuredDebtMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
"label": "Unsecured Debt [Member]",
"terseLabel": "Unsecured Debt [Member]"
}
}
},
"localname": "UnsecuredDebtMember",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LongtermDebtDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_UseOfEstimates": {
"auth_ref": [
"r151",
"r152",
"r153",
"r154",
"r161",
"r162",
"r163"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
"label": "Use of Estimates, Policy [Policy Text Block]",
"terseLabel": "Use of Estimates"
}
}
},
"localname": "UseOfEstimates",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
"auth_ref": [
"r414"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
"label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
"negatedTerseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
"terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount"
}
}
},
"localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/IncomeTaxesComponentsofNetDeferredIncomeTaxAssetsandLiabilitiesDetails",
"http://www.escalonmed.com/role/IncomeTaxesOperationlosscarryforwardDetails",
"http://www.escalonmed.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
"auth_ref": [
"r110"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
"label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
"terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense"
}
}
},
"localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/SignificantAccountingPoliciesAccountsReceivableDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_VariableRateAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of variable rate.",
"label": "Variable Rate [Axis]",
"terseLabel": "Variable Rate [Axis]"
}
}
},
"localname": "VariableRateAxis",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditDetails",
"http://www.escalonmed.com/role/LongtermDebtDetails",
"http://www.escalonmed.com/role/LongtermDebtEIDLmaturitiesTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_VariableRateDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
"label": "Variable Rate [Domain]",
"terseLabel": "Variable Rate [Domain]"
}
}
},
"localname": "VariableRateDomain",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/LineofcreditDetails",
"http://www.escalonmed.com/role/LongtermDebtDetails",
"http://www.escalonmed.com/role/LongtermDebtEIDLmaturitiesTables"
],
"xbrltype": "domainItemType"
},
"us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
"auth_ref": [
"r130",
"r142"
],
"calculation": {
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"lang": {
"en-us": {
"role": {
"documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
"label": "Weighted Average Number of Shares Outstanding, Diluted",
"totalLabel": "Weighted average shares - diluted"
}
}
},
"localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
"auth_ref": [
"r128",
"r142"
],
"calculation": {
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails": {
"order": 1.0,
"parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
"label": "Weighted Average Number of Shares Outstanding, Basic",
"terseLabel": "Weighted average shares - basic",
"verboseLabel": "Basic Weighted average shares outstanding"
}
}
},
"localname": "WeightedAverageNumberOfSharesOutstandingBasic",
"nsuri": "http://fasb.org/us-gaap/2022",
"presentation": [
"http://www.escalonmed.com/role/ConsolidatedStatementsOfOperations",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesEarningpersharedetailsDetails",
"http://www.escalonmed.com/role/SignificantAccountingPoliciesNetIncomelossPerShareDetails"
],
"xbrltype": "sharesItemType"
}
},
"unitCount": 4
}
},
"std_ref": {
"r0": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "105",
"URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
},
"r1": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "105",
"URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
},
"r10": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r100": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
},
"r101": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(c))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r102": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(e)(1))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r103": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(f))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r104": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r105": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r106": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h)(1))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r107": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h)(2))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r108": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(k)(1))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r109": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-04(a))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
},
"r11": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r110": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-09(Column C)(1))",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
},
"r111": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "235",
"URI": "https://asc.fasb.org/topic&trid=2122369"
},
"r112": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
},
"r113": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
},
"r114": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
},
"r115": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r116": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r117": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r118": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r119": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
},
"r12": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r120": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
},
"r121": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
},
"r122": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
},
"r123": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
},
"r124": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
},
"r125": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
},
"r126": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
},
"r127": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.M.Q2)",
"Topic": "250",
"URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
},
"r128": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
},
"r129": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
},
"r13": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
},
"r130": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
},
"r131": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
},
"r132": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
},
"r133": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)(1)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
},
"r134": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
},
"r135": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
},
"r136": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
},
"r137": {
"Name": "Accounting Standards Codification",
"Paragraph": "42",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256"
},
"r138": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
},
"r139": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
},
"r14": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
},
"r140": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
},
"r141": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
},
"r142": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r143": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r144": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r145": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
},
"r146": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
},
"r147": {
"Name": "Accounting Standards Codification",
"Paragraph": "52",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
},
"r148": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "270",
"URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305"
},
"r149": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
},
"r15": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 201.5-02(24))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r150": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r151": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r152": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r153": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
},
"r154": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
},
"r155": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
},
"r156": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
},
"r157": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
},
"r158": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
},
"r159": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
},
"r16": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 201.5-02(25))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r160": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
},
"r161": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
},
"r162": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
},
"r163": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
},
"r164": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "275",
"URI": "https://asc.fasb.org/extlink&oid=99380358&loc=d3e7102-108593"
},
"r165": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "275",
"URI": "https://asc.fasb.org/topic&trid=2134479"
},
"r166": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
},
"r167": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r168": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r169": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r17": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 201.5-02(26))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r170": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r171": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r172": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r173": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r174": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r175": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(j)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r176": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
},
"r177": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
},
"r178": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
},
"r179": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r18": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r180": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r181": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r182": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
},
"r183": {
"Name": "Accounting Standards Codification",
"Paragraph": "31",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
},
"r184": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r185": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r186": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r187": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r188": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
},
"r189": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
},
"r19": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(13))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r190": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
},
"r191": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
},
"r192": {
"Name": "Accounting Standards Codification",
"Paragraph": "42",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
},
"r193": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
},
"r194": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
},
"r195": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
},
"r196": {
"Name": "Accounting Standards Codification",
"Paragraph": "11B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
},
"r197": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
},
"r198": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
},
"r199": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
},
"r2": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "205",
"URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
},
"r20": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(14))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r200": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
},
"r201": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 4.E)",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
},
"r202": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "310",
"URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
},
"r203": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "323",
"URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
},
"r204": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "323",
"URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
},
"r205": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
},
"r206": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(3)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
},
"r207": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)(4)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
},
"r208": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
},
"r209": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
},
"r21": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(16))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r210": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
},
"r211": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
},
"r212": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
},
"r213": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(f)",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
},
"r214": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
},
"r215": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "330",
"URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
},
"r216": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "330",
"URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
},
"r217": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 5.BB)",
"Topic": "330",
"URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
},
"r218": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "330",
"URI": "https://asc.fasb.org/topic&trid=2126998"
},
"r219": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "340",
"URI": "https://asc.fasb.org/extlink&oid=126905361&loc=d3e8275-108329"
},
"r22": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(17))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r220": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "340",
"URI": "https://asc.fasb.org/extlink&oid=126905392&loc=d3e8384-108330"
},
"r221": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
},
"r222": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r223": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r224": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r225": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r226": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r227": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(f)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r228": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r229": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r23": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(18))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r230": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r231": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
},
"r232": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
},
"r233": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "30",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=121554622&loc=d3e15372-109273"
},
"r234": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
},
"r235": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
},
"r236": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
},
"r237": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r238": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(1)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r239": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(3)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r24": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(19)(a))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r240": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r241": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r242": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
},
"r243": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(b),(d)",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
},
"r244": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"SubTopic": "30",
"Topic": "350",
"URI": "https://asc.fasb.org/subtopic&trid=2144471"
},
"r245": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "30",
"SubTopic": "40",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280"
},
"r246": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "50",
"Topic": "350",
"URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286"
},
"r247": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228"
},
"r248": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r249": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r25": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(19))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r250": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r251": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
},
"r252": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "360",
"URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
},
"r253": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "410",
"URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
},
"r254": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r255": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.4(d))",
"Topic": "420",
"URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r256": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "440",
"URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
},
"r257": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "440",
"URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
},
"r258": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "440",
"URI": "https://asc.fasb.org/topic&trid=2144648"
},
"r259": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
},
"r26": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(20))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r260": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
},
"r261": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
},
"r262": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "20",
"Subparagraph": "(SAB Topic 5.Y.Q2)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
},
"r263": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "20",
"Subparagraph": "(SAB Topic 5.Y.Q4)",
"Topic": "450",
"URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
},
"r264": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "450",
"URI": "https://asc.fasb.org/topic&trid=2127136"
},
"r265": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "10",
"Topic": "460",
"URI": "https://asc.fasb.org/extlink&oid=126907644&loc=d3e11281-110244"
},
"r266": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "460",
"URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12524-110249"
},
"r267": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "460",
"URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249"
},
"r268": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
},
"r269": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
},
"r27": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(22))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r270": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r271": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r272": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r273": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r274": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r275": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r276": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
},
"r277": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r278": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r279": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r28": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(23))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r280": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r281": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r282": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r283": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r284": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
},
"r285": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r286": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r287": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r288": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r289": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r29": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(24))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r290": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(f)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r291": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r292": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r293": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(i)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r294": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r295": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
},
"r296": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
},
"r297": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
},
"r298": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r299": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r3": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "205",
"URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
},
"r30": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(26)(a))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r300": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r301": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r302": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r303": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r304": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r305": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r306": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r307": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r308": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r309": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r31": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(26)(b))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r310": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r311": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r312": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r313": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
},
"r314": {
"Name": "Accounting Standards Codification",
"Paragraph": "69B",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
},
"r315": {
"Name": "Accounting Standards Codification",
"Paragraph": "69C",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
},
"r316": {
"Name": "Accounting Standards Codification",
"Paragraph": "69E",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
},
"r317": {
"Name": "Accounting Standards Codification",
"Paragraph": "69F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
},
"r318": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "470",
"URI": "https://asc.fasb.org/topic&trid=2208564"
},
"r319": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r32": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(26)(c))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r320": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r321": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r322": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r323": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r324": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(i)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r325": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
},
"r326": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r327": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r328": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
},
"r329": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496177-112644"
},
"r33": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(27))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r330": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
},
"r331": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
},
"r332": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r333": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r334": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
},
"r335": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
},
"r336": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
},
"r337": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
},
"r338": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
},
"r339": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
},
"r34": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r340": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
},
"r341": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
},
"r342": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.3-04)",
"Topic": "505",
"URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
},
"r343": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "505",
"URI": "https://asc.fasb.org/topic&trid=2208762"
},
"r344": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
},
"r345": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
},
"r346": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
},
"r347": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
},
"r348": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
},
"r349": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
},
"r35": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(29))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r350": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
},
"r351": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "606",
"URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
},
"r352": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "10",
"Topic": "710",
"URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361"
},
"r353": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "30",
"SubTopic": "10",
"Topic": "710",
"URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
},
"r354": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "712",
"URI": "https://asc.fasb.org/extlink&oid=6410195&loc=d3e80090-111668"
},
"r355": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "712",
"URI": "https://asc.fasb.org/topic&trid=2197446"
},
"r356": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
},
"r357": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r358": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(i)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r359": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(k)(1)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r36": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r360": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(d)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
},
"r361": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(f)(3)",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
},
"r362": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "80",
"Topic": "715",
"URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
},
"r363": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
},
"r364": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
},
"r365": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r366": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r367": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(3)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r368": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r369": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r37": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(3))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r370": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r371": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r372": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r373": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r374": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r375": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r376": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(04)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r377": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r378": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r379": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r38": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r380": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(01)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r381": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r382": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(03)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r383": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r384": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r385": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r386": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r387": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r388": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r389": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r39": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(31))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r390": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r391": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(i)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r392": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(ii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r393": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iii)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r394": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(iv)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r395": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)(2)(v)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r396": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r397": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
},
"r398": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5444-113901"
},
"r399": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r4": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "205",
"URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
},
"r40": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(32))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r400": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r401": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
},
"r402": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "35",
"Subparagraph": "(b)",
"Topic": "720",
"URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
},
"r403": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "730",
"URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
},
"r404": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
},
"r405": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
},
"r406": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
},
"r407": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
},
"r408": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
},
"r409": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
},
"r41": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(4))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r410": {
"Name": "Accounting Standards Codification",
"Paragraph": "19",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
},
"r411": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
},
"r412": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
},
"r413": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
},
"r414": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
},
"r415": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
},
"r416": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
},
"r417": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
},
"r418": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
},
"r419": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
},
"r42": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r420": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
},
"r421": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
},
"r422": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
},
"r423": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
},
"r424": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r425": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(3)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
},
"r426": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r427": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.I.7)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r428": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.I.Fact.1)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r429": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.I.Fact.2)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r43": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(3))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r430": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.I.Fact.3)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r431": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.I.Fact.4)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r432": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.C)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
},
"r433": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "270",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
},
"r434": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
},
"r435": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "740",
"URI": "https://asc.fasb.org/topic&trid=2144680"
},
"r436": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
},
"r437": {
"Name": "Accounting Standards Codification",
"Paragraph": "31",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
},
"r438": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "50",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495"
},
"r439": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "30",
"SubTopic": "50",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498"
},
"r44": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(4))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r440": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "30",
"SubTopic": "50",
"Topic": "805",
"URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498"
},
"r441": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r442": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r443": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
},
"r444": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r445": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "810",
"URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r446": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(a)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
},
"r447": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(b)(2)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r448": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(3)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r449": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(4)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r45": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r450": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)",
"Topic": "815",
"URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
},
"r451": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "60",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
},
"r452": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
},
"r453": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
},
"r454": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
},
"r455": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
},
"r456": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
},
"r457": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "825",
"URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
},
"r458": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "230",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
},
"r459": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
},
"r46": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(b))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r460": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r461": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r462": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r463": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r464": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
},
"r465": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "830",
"URI": "https://asc.fasb.org/topic&trid=2175825"
},
"r466": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
},
"r467": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
},
"r468": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
},
"r469": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
},
"r47": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(c))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r470": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
},
"r471": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
},
"r472": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "840",
"URI": "https://asc.fasb.org/topic&trid=2208923"
},
"r473": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(1)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
},
"r474": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
},
"r475": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
},
"r476": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
},
"r477": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
},
"r478": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
},
"r479": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
},
"r48": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r480": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(3)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
},
"r481": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(1)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r482": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(3)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r483": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(4)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r484": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
},
"r485": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
},
"r486": {
"Name": "Accounting Standards Codification",
"Paragraph": "53",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
},
"r487": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org/subtopic&trid=77888251"
},
"r488": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(3)",
"Topic": "842",
"URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981"
},
"r489": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "845",
"URI": "https://asc.fasb.org/extlink&oid=126934811&loc=d3e32049-108421"
},
"r49": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(8))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r490": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "845",
"URI": "https://asc.fasb.org/topic&trid=2127423"
},
"r491": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(a)(3)(iii)(01)",
"Topic": "848",
"URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
},
"r492": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(a)(3)(iii)(03)",
"Topic": "848",
"URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
},
"r493": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "850",
"URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r494": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "850",
"URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r495": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "850",
"URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r496": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
},
"r497": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
},
"r498": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
},
"r499": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "850",
"URI": "https://asc.fasb.org/topic&trid=2122745"
},
"r5": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "205",
"URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
},
"r50": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(9))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r500": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r501": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r502": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "852",
"URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
},
"r503": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "855",
"URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
},
"r504": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r505": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r506": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r507": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r508": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r509": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r51": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a)(1),20)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r510": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "910",
"URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
},
"r511": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "330",
"Topic": "912",
"URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
},
"r512": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "730",
"Topic": "912",
"URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
},
"r513": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.L)",
"Topic": "924",
"URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
},
"r514": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "926",
"URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
},
"r515": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "340",
"Topic": "928",
"URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
},
"r516": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(1)(a))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r517": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(11))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r518": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(13))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r519": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(15)(2))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r52": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r520": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(15)(5))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r521": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(15))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r522": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(16))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r523": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(23))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r524": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.15(5))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
},
"r525": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(22))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r526": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(27))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r527": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04.9)",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r528": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "235",
"Subparagraph": "(SX 210.9-05(b)(2))",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
},
"r529": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "360",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
},
"r53": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a),20,24)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r530": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "470",
"Subparagraph": "e",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
},
"r531": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "470",
"Topic": "942",
"URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
},
"r532": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(15)(b)(2))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r533": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(16))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r534": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(12))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r535": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(15)(a))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r536": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(15))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r537": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r538": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(16))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r539": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(2))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r54": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(b),22(b))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r540": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r541": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(25))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r542": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(8))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r543": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.15(a))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
},
"r544": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(18))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r545": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(23))",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r546": {
"Name": "Accounting Standards Codification",
"Paragraph": "4H",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
},
"r547": {
"Name": "Accounting Standards Codification",
"Paragraph": "7A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(d)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
},
"r548": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(a)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
},
"r549": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(b)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
},
"r55": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r550": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(c)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
},
"r551": {
"Name": "Accounting Standards Codification",
"Paragraph": "29F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
},
"r552": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r553": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(1)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r554": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r555": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(1)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r556": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(i)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r557": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(ii)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r558": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(iii)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r559": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(iv)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r56": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19-26)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r560": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(h)(1)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r561": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(h)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r562": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "825",
"Topic": "944",
"URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
},
"r563": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "310",
"Subparagraph": "(SX 210.12-29(Footnote 4))",
"Topic": "948",
"URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
},
"r564": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Topic": "954",
"URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
},
"r565": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "440",
"Subparagraph": "(a)",
"Topic": "954",
"URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
},
"r566": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "360",
"Subparagraph": "(d)",
"Topic": "958",
"URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
},
"r567": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "360",
"Topic": "958",
"URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
},
"r568": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column B))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r569": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column C))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r57": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.20)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r570": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column D))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r571": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column E))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r572": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column F))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r573": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column G))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r574": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column H))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r575": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column I))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r576": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Footnote 2))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r577": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Footnote 5))",
"Topic": "970",
"URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r578": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(c)",
"Topic": "976",
"URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
},
"r579": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(b)",
"Topic": "978",
"URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
},
"r58": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.21)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r580": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "985",
"URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
},
"r581": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2"
},
"r582": {
"Name": "Form 10-K",
"Number": "249",
"Publisher": "SEC",
"Section": "310"
},
"r583": {
"Name": "Form 20-F",
"Number": "249",
"Publisher": "SEC",
"Section": "220",
"Subsection": "f"
},
"r584": {
"Name": "Form 40-F",
"Number": "249",
"Publisher": "SEC",
"Section": "240",
"Subsection": "f"
},
"r585": {
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Publisher": "SEC",
"Section": "13",
"Subsection": "a-1"
},
"r586": {
"Name": "Regulation S-T",
"Number": "232",
"Publisher": "SEC",
"Section": "405"
},
"r587": {
"Name": "Securities Act",
"Number": "230",
"Publisher": "SEC",
"Section": "405"
},
"r59": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r6": {
"Name": "Accounting Standards Codification",
"Paragraph": "5B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "205",
"URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
},
"r60": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r61": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.24)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r62": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-31)",
"Topic": "210",
"URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r63": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
},
"r64": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
},
"r65": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
},
"r66": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
},
"r67": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
},
"r68": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
},
"r69": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(210.5-03(11))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r7": {
"Name": "Accounting Standards Codification",
"Paragraph": "5C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(2)",
"Topic": "205",
"URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
},
"r70": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(1))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r71": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(20))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r72": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(25))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r73": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(5))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r74": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r75": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.2(a),(d))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r76": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.4)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r77": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.7(b))",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r78": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.7)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r79": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.9)",
"Topic": "220",
"URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
},
"r8": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "205",
"URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
},
"r80": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
},
"r81": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
},
"r82": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
},
"r83": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
},
"r84": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
},
"r85": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
},
"r86": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
},
"r87": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
},
"r88": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r89": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r9": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"SubTopic": "40",
"Topic": "205",
"URI": "https://asc.fasb.org/subtopic&trid=51888271"
},
"r90": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
},
"r91": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
},
"r92": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
},
"r93": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
},
"r94": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
},
"r95": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
},
"r96": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
},
"r97": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
},
"r98": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
},
"r99": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "235",
"URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
}
},
"version": "2.1"
} |
